<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">106156</article-id>
<article-id pub-id-type="doi">10.7554/eLife.106156</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.106156.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Biochemistry and Chemical Biology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Aggregation-Dependent Epitope Sequence and Modification Fingerprints of Anti-Aβ Antibodies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5617-8869</contrib-id>
<name>
<surname>Talucci</surname>
<given-names>Ivan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leske</surname>
<given-names>Timon</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Klafki</surname>
<given-names>Hans-Wolfgang</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="no">
<name>
<surname>Hassan</surname>
<given-names>Mohammed Mehedi</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Steiert</surname>
<given-names>Annik</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morgado</surname>
<given-names>Barbara</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6408-6112</contrib-id>
<name>
<surname>Bothe</surname>
<given-names>Sebastian</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Werven</surname>
<given-names>Lars</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liepold</surname>
<given-names>Thomas</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4678-2912</contrib-id>
<name>
<surname>Walter</surname>
<given-names>Jochen</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2067-3187</contrib-id>
<name>
<surname>Schindelin</surname>
<given-names>Hermann</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1492-5330</contrib-id>
<name>
<surname>Wiltfang</surname>
<given-names>Jens</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4115-0334</contrib-id>
<name>
<surname>Wirths</surname>
<given-names>Oliver</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3397-8924</contrib-id>
<name>
<surname>Jahn</surname>
<given-names>Olaf</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2719-4752</contrib-id>
<name>
<surname>Maric</surname>
<given-names>Hans Michael</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<email>hans.maric@uni-wuerzburg.de</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00fbnyb24</institution-id><institution>Rudolf Virchow Center for Integrative and Translational Bioimaging, Julius-Maximilians-Universität (JMU) Würzburg</institution></institution-wrap>, <city>Würzburg</city>, <country country="DE">Germany</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03pvr2g57</institution-id><institution>Department of Neurology, University Hospital Wuerzburg (UKW)</institution></institution-wrap>, <city>Würzburg</city>, <country country="DE">Germany</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/021ft0n22</institution-id><institution>Department of Psychiatry and Psychotherapy, University Medical Center Göttingen (UMG)</institution></institution-wrap>, <city>Göttingen</city>, <country country="DE">Germany</country></aff>
<aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03av75f26</institution-id><institution>Neuroproteomics Group, Department of Molecular Neurobiology, Max Planck Institute for Multidisciplinary Sciences</institution></institution-wrap>, <city>Göttingen</city>, <country country="DE">Germany</country></aff>
<aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01xnwqx93</institution-id><institution>Center of Neurology, Molecular Cell Biology, University Hospital Bonn</institution></institution-wrap>, <city>Bonn</city>, <country country="DE">Germany</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Lourenco</surname>
<given-names>Mychael V</given-names>
</name>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1078-0296</contrib-id><role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/03490as77</institution-id><institution>Universidade Federal do Rio de Janeiro</institution>
</institution-wrap>
<city>Rio de Janeiro</city>
<country>Brazil</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Dötsch</surname>
<given-names>Volker</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University Frankfurt</institution>
</institution-wrap>
<city>Frankfurt am Main</city>
<country>Germany</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="coi-statement"><p>Competing interests: No competing interests declared</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-05-09">
<day>09</day>
<month>05</month>
<year>2025</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2025-11-20">
<day>20</day>
<month>11</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP106156</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-02-14">
<day>14</day>
<month>02</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2025-03-03">
<day>03</day>
<month>03</month>
<year>2025</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.02.26.640323"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2025-05-09">
<day>09</day>
<month>05</month>
<year>2025</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.106156.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.106156.1.sa2">eLife Assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.106156.1.sa1">Reviewer #1 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.106156.1.sa0">Reviewer #2 (Public review):</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2025, Talucci et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Talucci et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-106156-v2.pdf"/>
<abstract><p>A hallmark of Alzheimer’s disease (AD), the most common form of dementia, is the progressive accumulation of amyloid-beta (Aβ) peptides across distinct brain regions. Anti-Aβ antibodies (Aβ-Abs) targeting specific Aβ variants are essential tools for AD research, diagnostics, and therapy. The monoclonal antibodies Aducanumab, Lecanemab, and Donanemab have recently been approved as the first disease-modifying treatments for early AD, highlighting the clinical importance of their exact binding profiles.</p>
<p>In this study, we systematically characterized the binding and modification requirements of 20 Aβ-Abs, including biosimilars of Aducanumab, Lecanemab, and Donanemab, across monomeric, oligomeric, and aggregated Aβ forms. Array-based analysis of 20,000 modified Aβ peptides defined binding epitopes at single-residue resolution and revealed the impact of sequence variation, including familial AD mutations, as well as diverse post-translational modifications (PTMs). Notably, genetic variants such as H6R impaired binding of therapeutic Aβ-Abs like Aducanumab. Donanemab showed strong preference for pyroglutamate-modified AβpE3–10, while Lecanemab and Aducanumab exhibited aggregation- and sequence-context-dependent binding requirements.</p>
<p>Comparison of peptide binding profiles with binding of full-length and aggregated Aβ via immunoprecipitation-mass spectrometry, capillary immunoassays, Western blotting, and immunohistochemistry on AD brain tissue revealed distinct aggregation-dependent binding behaviours. The valency- and context-dependence of Aducanumab binding, together with its preference for Ser8-phosphorylated Aβ, supports a dimerization-mediated binding mechanism. For Lecanemab, our data suggest that additional structural contributions beyond the minimal N-terminal epitope are required for binding to aggregated Aβ, which remain to be fully resolved.</p>
<p>Together, this work provides the most comprehensive dataset to date on aggregation-dependent sequence and modification selectivity of Aβ-Abs. By integrating mutational, PTM, and aggregation contexts in a unified experimental framework, we establish a resource that enables rational selection of antibodies for research and diagnostic applications, and offers mechanistic insights that may inform the design and optimization of future therapeutic antibodies in AD.</p>
</abstract>
<funding-group>
<award-group id="funding-1">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/018mejw64</institution-id>
<institution>Deutsche Forschungsgemeinschaft</institution>
</institution-wrap>
</funding-source>
<award-id>MA6957/1-1</award-id>
</award-group>
<award-group id="funding-1a">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/018mejw64</institution-id>
<institution>Deutsche Forschungsgemeinschaft</institution>
</institution-wrap>
</funding-source>
<award-id>WI3472/11-1</award-id>
</award-group>
<award-group id="funding-1b">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/018mejw64</institution-id>
<institution>Deutsche Forschungsgemeinschaft</institution>
</institution-wrap>
</funding-source>
<award-id>WA1477/6-6</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Addition of IP-MS data from human CSF and aggregation-sensitive blocking studies; Results and Discussion present and fully discuss differences between aggregated and non-aggregated forms of full-length and truncated Abeta species; added clinical context for therapeutic antibodies; updated Conclusions to integrate mechanistic insights; revised text, tables and figures and supplemental data for clarity.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) [<xref ref-type="bibr" rid="c1">1</xref>,<xref ref-type="bibr" rid="c2">2</xref>] and tau tangles in the brain, leading to cognitive decline and dementia [<xref ref-type="bibr" rid="c3">3</xref>]. Aβ peptides are generated under physiological conditions from Amyloid Precursor Protein (APP) by sequential proteolytic cleavages by beta- and gamma-secretase [<xref ref-type="bibr" rid="c4">4</xref>]. The initial β-secretase cleavage of APP results in the release of soluble sAPPβ and the generation of a 99 amino acids (AA) long carboxy (C)-terminal APP fragment (C99) with an amino (N)-terminal Asp-residue. Aβ peptides are generated by subsequent gamma-secretase cleavage of C99 [<xref ref-type="bibr" rid="c5">5</xref>,<xref ref-type="bibr" rid="c6">6</xref>].</p>
<p>In human cerebrospinal fluid, a conserved pattern of soluble Aβ1-37, Aβ1-38, Aβ1-39, Aβ1- 40 and Aβ1-42 has been observed [<xref ref-type="bibr" rid="c7">7</xref>]. Aβ peptides isolated from amyloid plaques have been shown to include several variants differing in length, their N- and C-termini, and post- translational modifications (PTMs) [<xref ref-type="bibr" rid="c8">8</xref>], such as cyclization of N-terminal Glu(3) or Glu(11) into pyroglutamate (pE) [<xref ref-type="bibr" rid="c9">9</xref>], and racemization or isomerization of Asp(1) and Asp(7) [<xref ref-type="bibr" rid="c10">10</xref>–<xref ref-type="bibr" rid="c13">13</xref>]. Furthermore, phosphorylated forms of Aβ (pSer(8) and pSer(26)) have been reported in amyloid plaques based on studies employing phospho-selective anti-Aβ antibodies (Aβ-Abs), although these findings have not yet been conclusively confirmed by mass spectrometry [<xref ref-type="bibr" rid="c14">14</xref>–<xref ref-type="bibr" rid="c16">16</xref>]. In extracellular senile plaques in the brain’s functional tissue, the parenchyma, Aβ1-42 is more prevalent than Aβ1-40, and various N- and C-terminally truncated [<xref ref-type="bibr" rid="c17">17</xref>–<xref ref-type="bibr" rid="c20">20</xref>] as well as N- terminally elongated variants [<xref ref-type="bibr" rid="c21">21</xref>] have been described [<xref ref-type="bibr" rid="c5">5</xref>,<xref ref-type="bibr" rid="c22">22</xref>]. In particular, those starting with a cyclized pE (3) [<xref ref-type="bibr" rid="c12">12</xref>] or Phe at position 4 [<xref ref-type="bibr" rid="c21">21</xref>,<xref ref-type="bibr" rid="c23">23</xref>], are highly abundant in AD brains [<xref ref-type="bibr" rid="c24">24</xref>]. Genetic mutations [<xref ref-type="bibr" rid="c25">25</xref>] further multiply Aβ amino acid sequence variability. The study of the structural polymorphisms of the Aβ peptide resulting from PTMs or mutations and the potential impact on the formation of pathophysiological oligomeric forms and fibrillar aggregates is challenging [<xref ref-type="bibr" rid="c26">26</xref>–<xref ref-type="bibr" rid="c30">30</xref>]. The majority of PTMs occur in the flexible N-terminal region of the fibrils, encompassing residues 1–16, and were proposed to trigger or accelerate the fibrillation of Aβ [<xref ref-type="bibr" rid="c31">31</xref>–<xref ref-type="bibr" rid="c33">33</xref>]. The same region is responsible for metal ion coordination which may also influence fibril formation [<xref ref-type="bibr" rid="c34">34</xref>]. Similarly, several pathogenic APP mutations within Aβ are associated with altered folds, higher aggregation propensities, and toxicities [<xref ref-type="bibr" rid="c35">35</xref>–<xref ref-type="bibr" rid="c37">37</xref>].</p>
<p>Importantly, this complexity requires molecular tools with appropriate molecular specificity and sensitivity and poses enormous challenges in designing sensitive diagnostic readouts and effective targeted therapies. Passive immunotherapy using monoclonal Aβ-Abs has been investigated extensively as an approach for AD treatment resulting in Aβ-Abs with several different Aβ selectivity profiles [<xref ref-type="bibr" rid="c38">38</xref>] [<xref ref-type="bibr" rid="c39">39</xref>]. For example, Aducanumab, a recombinant human antibody, was developed after screening human memory B-cells for reactivity towards aggregated Aβ [<xref ref-type="bibr" rid="c40">40</xref>,<xref ref-type="bibr" rid="c41">41</xref>]. Bapineuzumab, the humanized form of the murine antibody 3D6 [<xref ref-type="bibr" rid="c42">42</xref>] has been reported to bind to both monomeric and aggregated Aβ.</p>
<p>Despite extensive structural, genetic, and pre-clinical investigations, clinical trials of Aβ antibodies have yielded ambiguous outcomes. Aβ antibody binding to cerebral amyloid angiopathy (CAA) has been hypothesized to correlate with the frequency of amyloid-related imaging abnormalities with edema (ARIA-E) observed in patients treated with Aβ-based immunotherapies [<xref ref-type="bibr" rid="c38">38</xref>]. Aducanumab, developed by Neurimmune AG and later licensed to Biogen. was investigated in two parallel Phase 3 clinical trials: EMERGE demonstrated statistically significantly slower decline in the Clinical Dementia Rating Sum of Boxes for a high dose of Aducanumab vs. placebo, while ENGAGE failed to meet its primary endpoints [<xref ref-type="bibr" rid="c43">43</xref>]. Marketing and development of Aducanumab was halted in 2024 [<xref ref-type="bibr" rid="c44">44</xref>]. Lecanemab was designed at Uppsala University, humanized by BioArctic, and later licensed to Eisai. It showed positive results in the Clarity AD trial, and, cross-study comparison suggested that Lecanemab [<xref ref-type="bibr" rid="c45">45</xref>,<xref ref-type="bibr" rid="c46">46</xref>] has lower ARIA-E frequency than Aducanumab (13% vs 25-35%) [<xref ref-type="bibr" rid="c38">38</xref>], Lecanemab is now marketed as Leqembi. Eli Lilly’s Donanemab, approved in the US as Kisunla, binds to CAA fibrils in proportion to the amount of pyroglutamate-modified Aβ they present [<xref ref-type="bibr" rid="c38">38</xref>] [<xref ref-type="bibr" rid="c47">47</xref>]. These divergent outcomes highlight the importance of thoroughly characterizing each antibody’s epitope specificity, binding affinity for Aβ variants, ability to access relevant brain compartments, and possible genetic confounders (such as APOE ε4).</p>
<p>Aβ-Abs are the primary means for the detection and targeting of specific Aβ variants within the outlined Aβ-sequence and -modification space. The precise molecular binding epitopes of Aβ-Abs are fundamental to Aβ research. However, the immunogens used to raise and select Aβ-Abs may not represent precise and reliable predictors of the actual sequence and modification requirements. Furthermore, epitope requirements reported by different mapping methodologies may differ and may thus render a comparison difficult. Here we addressed the range and limitations of the sequence and modification specificity by side-by-side comparison in complementary assays for a panel of 20 Aβ-Abs central to AD research and therapy.</p>
</sec>
<sec id="s2">
<title>Results and Discussion</title>
<p>The Aβ-Abs investigated in this study are listed in <xref rid="tbl1" ref-type="table">Table 1</xref>. The panel encompasses biosimilars of the currently FDA-approved drugs (i) Aducanumab (Biogen), initially approved for the treatment of mild cognitive impairment [<xref ref-type="bibr" rid="c44">44</xref>] but discontinued in 2024 (ii) Lecanemab (Biogen, Uppsala University and Eisai) [<xref ref-type="bibr" rid="c48">48</xref>], which in contrast to Aducanumab, has been approved via regular approval track and (iii) Donanemab (Eli Lilly) as the most recent expansion of the AD- drug arsenal [<xref ref-type="bibr" rid="c49">49</xref>,<xref ref-type="bibr" rid="c50">50</xref>]. The set of Aβ-Abs further encompasses selected antibodies directed against specific Aβ variants such as Aβ1-x with a free N-terminal-Asp(1) (3D6, 82E1, 11H3, 80C2), N-truncated Aβ starting with pE(3) (AβpE3-x) (pE3-Aβ, 2-48 and Donanemab<sub>bs</sub>) and phosphorylated Aβ forms (1E4E11, 5H11C10). Furthermore, the panel covers Aβ-Abs against the N-terminal region of Aβ and a central epitope, as well as antibodies selective for N- terminally elongated and truncated Aβ variants.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1</label>
<caption><p><bold>Footnotes:</bold> (a) names of the anti-amyloid beta antibodies. (b) Source of the antibodies used in this study, either commercial or academic. (c) Clonality of the antibodies: &quot;mono&quot; indicates monoclonal, while &quot;poly&quot; stands for polyclonal antibodies. (d) Species of origin for the IgGs: mouse, rat, human, or rabbit. (e) Immunogens, as reported in the literature, that were used to generate the corresponding antibodies. (f) If available, the anticipated PTM specificity is indicated: “p” represents phosphoserine (at positions Ser8 or Ser26), and “pE3” refers to an N-terminal pyroglutamate (at position 3). (g) epitope identified in this study on microarrays.</p></caption>
<graphic xlink:href="640323v2_tbl1.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
<sec id="s2a">
<title>Pre-screening of Aβ-Ab Epitopes</title>
<p>Information regarding binding epitopes and /or immunogens for most of the tested Aβ-Abs has been published and is summarized in <xref rid="tbl1" ref-type="table">Table 1</xref>. However, the binding epitope information was derived from varying methodologies. To provide an initial side-by-side comparison we pre- screened all of the listed Aβ-Abs in array format using copies of peptide libraries and standard antibody concentrations of 0.5-1 µg/mL (<xref rid="fig1" ref-type="fig">Figure 1a</xref>). The library comprised the amyloid precursor protein (APP770) residues 649-722, corresponding to the canonical Aβ1-42 amino acid sequence with additional 23 amino terminal and 9 carboxy terminal residues. To enable single amino acid resolution, 60 peptides with a length of 15AA and overlapping by 14AA were synthesized and displayed as cellulose-conjugates incapable of oligomerization (<xref rid="fig1" ref-type="fig">Figure 1b</xref>). We first focused on Aβ-Abs with known preference for Aβ starting with a free Asp(1) and initially found that 3D6 and 82E1 also detected Aβ(2-x) and several N-terminally elongated Aβ-related peptides in addition to Aβ(1-x), at least under the generic pre-screening conditions with presumably suboptimal Ab concentrations (<xref rid="fig1" ref-type="fig">Figure 1b</xref>). Thus, it is clear that antibodies must be titrated for each specific application to obtain selectivity and to reduce non-specific binding. For optimal signal to noise ratios and ideal selectivity profiles on the microarrays, the Aβ-Ab concentrations were adjusted for 3D6, 82E1, 11H3, 80C2 and 7H3D6 (<xref rid="fig1s1" ref-type="fig">Figure 1 – figure-supplement 1</xref>) and (<bold>Appendix 1-7</bold>). This setup allowed to determine the general location of the binding epitopes within the Aβ sequence for all tested Aβ-Abs as shown by the heatmap in (<xref rid="fig1" ref-type="fig">Figure 1b</xref>). Similarly, Donanemab [<xref ref-type="bibr" rid="c47">47</xref>,<xref ref-type="bibr" rid="c64">64</xref>], 1E4E11 [<xref ref-type="bibr" rid="c57">57</xref>], and 5H11C10 [<xref ref-type="bibr" rid="c14">14</xref>], which have been previously reported as selective for AβpE3, pSer8Aβ, and pSer26-Aβ, respectively, produced detectable signals in this pre-screening with unmodified Aβ-related peptides. Again, these findings demonstrate the need for further investigation to confirm selectivity under more appropriate assay conditions, i.e. optimized antibody concentrations and presentation of modified Aβ-fragments as binding partners. The side-by-side determined epitopes are summarized together with their immunogen in <xref rid="tbl1" ref-type="table">Table 1</xref>. Epitope mapping recapitulated previously reported data, but also further confines (pAb77, 4G8, 14-2-4, 101-1- 1, 6E10, 1E8, 7H3D6, 1E4E11, 5H11C10) or even expands (Aducanumab<sub>bs</sub>) the required residues for binding. However, although this initial microarray only contained unmodified Aβ sequences, we also observed binding for Aβ-Abs known as PTM-selective. Specifically, Donanemab<sub>bs</sub>, 2-48 and Aβ-pE3 were raised against AβpE3-x (<xref rid="tbl1" ref-type="table">Table 1</xref>) and were expected to show preference for Aβ peptides starting with a pE(3). In the pre-screening with unmodified Aβ sequences, however, Donanemab<sub>bs</sub> detected Aβ(3-x) starting with non-cyclized Glu (3), Aβ(-3-x) as well as several other N-terminally elongated Aβ-related peptides and Aβ1-x. Since the primary binding mode for AβpE3-x had not yet been tested at this stage these initial screening observations remain preliminary. Similarly, 1E4E11 and 5H11C10, which were reported to have high selectivity for phosphorylated Aβ peptides at Ser8 and Ser26 [<xref ref-type="bibr" rid="c14">14</xref>,<xref ref-type="bibr" rid="c57">57</xref>], both displayed strong signals with several non-phosphorylated Aβ variants in the pre- screening. Although the findings with the modification-selective Aβ-Abs are indicative of cross-reactivity due to the presence of epitopes resembling their target and/or the effect of suboptimal binding conditions, the unbiased microarray screening provided valuable initial information regarding the sequence regions and modifications of interest to be investigated in more detail in the course of our study.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Microarray workflow and Aβ-Ab epitope pre-screening.</title>
<p>(a) Schematic of the microarray workflow. The library comprised the amyloid precursor protein (APP) residues 649-722 (APP770 numbering), corresponding to Aβ residues -23 to 51, as a library of 15-mer peptides overlapping by 14AAs, copied in dozens, and probed for Aβ-Abs binding followed by analysis in MARTin. (b) The epitope screening binding data are summarized as a heatmap. Blue and red shades indicate the relative binding strength of the related arrayed peptides to the left and cognate Aβ-Ab on top. The blue – red scale is visualizing the normalized binding intensity for each antibody individually. The applied antibody concentrations ranged between 0.5-1 µg/mL. Note: Among the 20 tested antibodies, 1E4E11, 5H11C10, 2-48, Aβ-pE3, and Donanemab<sub>bs</sub> have known PTM-selectivity, which could not be fully addressed with the initial microarray consisting of unmodified Aβ fragments only.</p></caption>
<graphic xlink:href="640323v2_fig1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2b">
<title>Titration and Selectivity Assessment of Aβ Abs Directed Against <bold>the Aβ N-terminus</bold></title>
<p>The sensitivity and selectivity profiles of Aβ-Abs 80C2, 11H3, 3D6, 82E1, which were expected to show preferential binding to Aβ with a free N-terminal Asp(1), and mAb 7H3D6 were explored in more detail. The canonical Aβ peptide is typically 40-42 amino acids long. In addition, various N-terminal variants have been reported [<xref ref-type="bibr" rid="c53">53</xref>]. Several truncated forms have been detected in brain tissue [<xref ref-type="bibr" rid="c21">21</xref>,<xref ref-type="bibr" rid="c24">24</xref>]. Notably, N-terminally truncated Aβ peptides, particularly those starting with Phe at position 4, are abundant in AD brains. The metalloproteinase ADAMTS4, which is expressed in oligodendrocytes, has been linked to APP processing and the generation of Aβ4-x peptides [<xref ref-type="bibr" rid="c23">23</xref>]. Additionally, N-terminally elongated Aβ peptides, such as Aβ(-3-x), which can be generated by the same enzyme in cell culture [<xref ref-type="bibr" rid="c21">21</xref>], may be of interest in the context of AD biomarker research: Aβ(-3-40) can serve as a reference in a composite blood-based biomarker of AD for cerebral Aβ accumulation [<xref ref-type="bibr" rid="c65">65</xref>,<xref ref-type="bibr" rid="c66">66</xref>]. Highly sensitive and selective Aβ-Abs for N-terminal Aβ variants are a prerequisite for studying their specific roles in detail. In our microarray experiments, the titration of Aβ-Abs expected to prefer Aβ1-x variants with a free N-terminal Asp (mAbs 80C2, 11H3, 3D6, 82E1) plus the rat monoclonal 7H3D6 (<xref rid="fig1s1" ref-type="fig">Figure 1 - figure supplement 1</xref>) (<bold>Appendix 1</bold>) broadly classifies the tested mAbs into two groups. One group (80C2 and 11H3) that, on microarray under the tested experimental conditions, displayed exclusive binding towards Aβ1-x over the entire titration range albeit with limited sensitivity. A second group showed high sensitivity but concentration-dependent and limited Aβ1-x selectivity over related Aβ variants under the tested conditions (3D6, 82E1 and 7H3D6). Among the 20 tested antibodies, 1E4E11, 5H11C10, 2-48, Aβ-pE3, and Donanemab<sub>bs</sub> exhibited the previously reported preferences for PTMs, which will be addressed in detail in the following paragraphs.</p>
</sec>
<sec id="s2c">
<title>Deep Mutational Scans Provide Information on Aβ-Abs Binding Requirements</title>
<p>Next, we further explored the reactivities observed during the epitope pre-screening (<xref rid="fig1" ref-type="fig">Figure 1</xref>) and probed in total 14 selected monoclonal antibodies with matched deep mutational libraries. Apart from the biosimilar Abs and the Abs directed against the Aβ N-terminus described above, we also selected three generic Aβ Abs as references (IC16, 1E8, 6E10) and two Abs selective for N-terminally elongated Aβ variants (14-2-4, 101-1-1), the core epitope of which we have described earlier [<xref ref-type="bibr" rid="c21">21</xref>]. Display and binding evaluation of all possible point- mutants systematically resolved the sequence requirements for these 14 Aβ-Abs towards the binding region corresponding to the Aβ(-10-18) amino acid sequence (<xref rid="fig2s1" ref-type="fig">Figure 2A - figure supplement 1</xref>) in three different 18-meric positional scans. Peptides covering Aβ(-10-8) (<xref rid="fig2" ref-type="fig">Figure 2b</xref>), Aβ(-3-15) (<xref rid="fig2" ref-type="fig">Figure 2c</xref>) and Aβ1-18 (<xref rid="fig2" ref-type="fig">Figure 2d</xref>) regions were generated. As these three peptide regions showed binding to most of the N-terminal antibodies (<xref rid="fig1" ref-type="fig">Figure 1</xref>), we postulated that these 18-mers should cover the main antigen-antibody (Ag/Ab) contact regions. The three Aβ-related wild-type sequences were sequentially scanned from N-terminus to C- terminus by replacing each position by every proteinogenic amino acid (342 different peptide sequences in total). A customized criterion was utilized to identify the core motif for each monoclonal antibody tested. While the identified core motifs are essential for binding, they may not fully represent the specificity of the antibodies but rather indicate where the majority of the Ag/Ab contact takes place. Specifically, the raw mean intensities for all peptide variants were measured and normalized against the corresponding wildtype sequence. Amino acid exchanges that reduced binding by &gt;50% were designated as dominant negative. This process was reiterated for each exchange at that position. Positions were considered as major contributor to the core motif when more than 50% of the exchanges were marked as dominant negative. The resulting core motifs are summarized in <xref rid="fig2s1" ref-type="fig">Figure 2 – figure supplement 1D</xref>. The findings highlight both similarities and differences in the binding mode of different Aβ-Abs, affirming binding to epitopes located in the N-terminal region of the Aβ sequence. Overall, this comprehensive binding data provides guidance for sorting monoclonal Aβ-Abs based on epitope properties. For two of the tested antibodies, namely 3D6 and Aducanumab, crystal structures are publicly available [<xref ref-type="bibr" rid="c41">41</xref>] [<xref ref-type="bibr" rid="c42">42</xref>], and indicate binding in the regions Aβ1-5 (3D6) and 3-7 (Aducanumab), respectively. Here, the microarray results recapitulated the epitope of 3D6 (murine precursor of Bapineuzumab) and expanded the binding interface for Aducanumab<sub>bs</sub> binding to monomeric short Aβ fragments by two residues, namely Asp(1) and Ala(2) (<xref rid="fig2" ref-type="fig">Figure 2D</xref>, <xref rid="fig2s1" ref-type="fig">Figure 2 - figure supplement 1A, B</xref>). Donanemab is known to recognize Aβ starting with cyclized pE3 [<xref ref-type="bibr" rid="c47">47</xref>,<xref ref-type="bibr" rid="c64">64</xref>], however, on our initial microarray screen, Donanemab<sub>bs</sub> showed clear signals with AβpE3-x and several other Aβ related peptides starting N-terminally of Glu(3), including Aβ1-x (<xref rid="fig1" ref-type="fig">Figure 1</xref>). To further explore this unexpected observation, Donanemab<sub>bs</sub> was tested on the Aβ (1-18) deep mutational scan. Consistent with its expected preference for the Aβ3-x region, the primary Ag/Ab contacts for the binding to Aβ1-18 involved the amino acids <italic>EFRHDSGY.</italic> Asp(1) and Ala(2) were not highly conserved. Importantly, the murine precursor antibody mE8 from which Donanemab was derived was previously shown to have a very strong preference for truncated AβpE3(starting with pyroglutamate) [<xref ref-type="bibr" rid="c64">64</xref>]. This particular point is further addressed in detail in the paragraph “Modification selectivity of monoclonal Aβ-Abs mAbs” (see below). The monoclonal Ab 1E4E11, which was previously reported to be highly selective for phosphorylated pSer(8)-Aβ [<xref ref-type="bibr" rid="c57">57</xref>], bound to unphosphorylated Aβ2-16 and several other unphosphorylated Aβ-related peptides on the initial screen (<xref rid="fig1" ref-type="fig">Figure 1</xref>). Interestingly, the profiling of Ser(8) did not show elevated binding to the phospho-mimetic exchanges (Asp or Glu) (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). The effect of phosphorylation at Ser(8) is also addressed in detail in the paragraph “Modification selectivity of monoclonal Aβ-Abs” mAbs (see below). As shown in (<xref rid="fig2s2" ref-type="fig">Figure 2 – figure supplement 2D</xref>), several Aβ-Abs exhibited altered binding strength with exchanges R5G or Y10F which may be valuable information when studying the co-aggregation dynamics between exogenous (human) and endogenous (mouse) Aβ in transgenic models.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Deep Mutational Scans Define Aβ-Ab Core Sequences</title>
<p>(a) Schematic summary of the three deep positional scans in the N-terminal region. Seven reported APP mutations are indicated as yellow boxes. From each 18-mer epitope, positional substitutions were generated (342 variants for each epitope) and tested semi-quantitatively in microarray format. The wild- type (wt) sequence was sequentially scanned from N to C terminal by turning each position into every proteinogenic amino acid. Consequently, the contribution of each residue is depicted in blue-white-red shades, with white corresponding to no variation from wt [<xref ref-type="bibr" rid="c1">1</xref>] and blue-to-red representing loss or gain of binding strength. (b) Fingerprint analysis for the first peptide group covering the sequence <italic>KTEEISEVKMDAEFRHDS</italic>. The Aβ-Abs tested here are <italic>101-1-1</italic> and <italic>14-2-4.</italic> (c) Fingerprint analysis for the second peptide group covering the sequence <italic>VKMDAEFRHDSGYEVHHQ</italic>. The Aβ-Abs tested here are IC16 and 1E8. (d) Fingerprint analysis for the third peptide group covering the sequence <italic>DAEFRHDSGYEVHHQKLV</italic>. The Aβ-Abs tested here are Aducanumab, Donanemab and Lecanemab biosimilars. In addition, commercially available Aβ-Abs such as 3D6, 82E1, 11H3, 80C2, 7H3D6 and 1E4E11 were included. Note: The antibodies, 1E4E11 and Donanemab<sub>bs</sub> have known reported PTM- preference which will be addressed in the next paragraphs.</p></caption>
<graphic xlink:href="640323v2_fig2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>The data set presents the sequence requirements of 14 Aβ-Abs for binding to 18-mer Aβ-related peptides in a microarray setup, thereby complementing previous structural insights and further improving our understanding of their molecular mode of action.</p>
</sec>
<sec id="s2d">
<title>Hereditary APP Mutations Affect Antibody Binding</title>
<p>Next, we studied the impact of some reported hereditary mutations in the <italic>APP</italic> gene resulting in amino acid exchanges within the Aβ sequence [<xref ref-type="bibr" rid="c25">25</xref>]. Specific familiar <italic>APP</italic> gene mutations [<xref ref-type="bibr" rid="c25">25</xref>,<xref ref-type="bibr" rid="c67">67</xref>] are reported to either lead to aggressive forms of AD or to exert a protective effect. Several mutations in the Aβ peptide have been reported to cause familial AD (fAD), with all but two having a dominant pattern of inheritance [<xref ref-type="bibr" rid="c67">67</xref>,<xref ref-type="bibr" rid="c68">68</xref>]. These alterations can lead to enhanced aggregation and increased cytotoxicity, contributing to the onset and progression of early-onset AD. The following APP mutations within the Aβ amino acid sequence were included in the microarray screen: D7H [<xref ref-type="bibr" rid="c69">69</xref>], D7N [<xref ref-type="bibr" rid="c70">70</xref>], H6R [<xref ref-type="bibr" rid="c71">71</xref>], A2V[<xref ref-type="bibr" rid="c72">72</xref>], A2T [<xref ref-type="bibr" rid="c73">73</xref>,<xref ref-type="bibr" rid="c74">74</xref>], K16Q [<xref ref-type="bibr" rid="c75">75</xref>,<xref ref-type="bibr" rid="c76">76</xref>], L17V [<xref ref-type="bibr" rid="c77">77</xref>].</p>
<p>Our analysis indicates that genetic mutations causing amino acid exchanges in or close to the Aβ sequence can affect antibody binding. Regarding the biosimilar antibodies Lecanemab<sub>bs</sub>, Donanemab<sub>bs</sub> and Aducanumab<sub>bs</sub>, this may potentially have relevance for rare fAD and their therapeutic implications. The APP mutants D7H/7N, H6R and A2T/V, K16Q and L17V are highlighted in the deep mutational scan data (<xref rid="fig2" ref-type="fig">Figure 2</xref> and <xref rid="fig2s1" ref-type="fig">Figure 2 – figure supplement 1</xref>), as they were identified within the core motifs of the Aβ-Abs. The mutations A2V, D7H, D7N, and H6R can lead to an increased aggregation propensity of Aβ and contribute to early onset fAD [<xref ref-type="bibr" rid="c78">78</xref>]. Specifically, D7H (Taiwan), D7N (Tottori), and H6R (English) mutations may alter the structural features and thermodynamics of Aβ42, leading to increased β-sheet [<xref ref-type="bibr" rid="c79">79</xref>] content. For confirmation and for highlighting the importance of considering genetic variability for therapeutic responses, we next paradigmatically explored the effects of the D7H, D7N, H6R, A2V and A2T APP mutations [<xref ref-type="bibr" rid="c71">71</xref>] on Aducanumab<sub>bs</sub> binding to short monomeric Aβ-related peptides on microarray.</p>
</sec>
<sec id="s2e">
<title>The Mutation H6R Abolishes Aducanumab Binding</title>
<p>Consistently across the two deep positional scans, Aducanumab<sub>bs</sub> and 6E10 showed significantly reduced binding intensity to 18-mer peptides on the array in case of the fAD H6R mutation [<xref ref-type="bibr" rid="c71">71</xref>]. This aligns closely with previous findings [<xref ref-type="bibr" rid="c55">55</xref>], which identified <italic>RXD</italic> as the minimal sequence required for 6E10 binding via phage mapping (present in 53% of immunoprecipitated sequences). Our data indicate that 6E10 exhibits binding to a broader motif, <italic>EFRHD</italic> and shows that H6 is necessary for binding. To confirm our findings and underscore the potential significance of genetic variability in possible therapeutic strategies, we subsequently measured the binding affinity of Aducanumab<sub>bs</sub> to Aβ(1-15, H6R) [<xref ref-type="bibr" rid="c71">71</xref>]. First, we spotted the corresponding purified peptides <italic>DAEFR<bold>H</bold>DSGYEVHHQ</italic> and <italic>DAEFR<bold>R</bold>DSGYEVHHQ</italic> (<xref rid="fig2s2" ref-type="fig">Figure 2 – figure supplement 2a</xref>) (<bold>Appendix 8</bold>) at 2-fold dilutions. The semi-quantitative on chip titration confirmed a reduced binding strength of Aducanumab<sub>bs</sub> for the H6R Aβ1-15 variant. For complete quantification including kinetic evaluation, we next conducted Biolayer Interferometry (BLI) experiments (<xref rid="fig2s2" ref-type="fig">Figure 2 – figure supplement 2b</xref>). The BLI response of Aducanumab<sub>bs</sub> for the H6R was completely abolished when compared with the wildtype sequence. These data confirm the array profiling and, in broader context, highlight a possible gap in efficacy for monoclonal Aβ-Abs in individuals with certain rare hereditary mutations associated with AD, which may have implications for personalized treatment approaches. However, whether or not the H6R amino acid replacement could impact also the binding of Aducanumab<sub>bs</sub> to aggregated Aβ is still unclear.</p>
</sec>
<sec id="s2f">
<title>Modification Selectivity of Monoclonal Aβ-Abs</title>
<p>PTMs of Aβ can significantly impact aggregation propensity [<xref ref-type="bibr" rid="c31">31</xref>], clearance mechanisms, and toxicity in AD. Specific PTMs might be associated with different stages of AD progression and severity, offering potential biomarkers for diagnosis and prognosis. Targeting PTMs represents a potential therapeutic strategy to prevent Aβ aggregation and neurotoxicity, thereby slowing disease progression. <italic>In vitro</italic>, Aβ cyclization of N-terminal Glu into pE, and racemization/isomerization of Asp were shown to increase the aggregation propensity and neurotoxicity [<xref ref-type="bibr" rid="c12">12</xref>,<xref ref-type="bibr" rid="c80">80</xref>]. Therefore, a selected group of PTM-carrying Aβ peptides (PTM-Aβ) were incorporated into the Aβ chip to explore the potential binding preference of selected Aβ- Abs, under optimized concentrations (<xref rid="fig3" ref-type="fig">Figure 3</xref>). The antibodies were tested with both PTM- Aβ and the corresponding unmodified variants to provide a head-to-head comparison. This screening was performed in the presence of Aβ phosphorylated at positions Ser(8) or Ser(26), N-terminal pE at position 3, racemization/isomerization of Asp at position 1, and unmodified N-terminal variants. The dataset is divided into sections (<xref rid="fig3" ref-type="fig">Figure 3 a-f</xref>) for enhanced visualization, where each antibody was screened simultaneously against all peptides to locate their epitope preferences. Post-hoc mass spectrometry (MS) analysis validated the correct display of the PTM variants included in the microarray (<bold>Appendix 1-6</bold>). A set of antibodies without reported PTM preference was applied here as controls (<bold>refer to </bold><xref rid="tbl1" ref-type="table">Table 1</xref>), namely 11H3, 101-1-1, IC16, 82E1 and 3D6. Antibody 6E10 has been previously shown to be unable to detect Aβ-pSer(8) and was thus also included as a control antibody [<xref ref-type="bibr" rid="c81">81</xref>]. On the microarray and under the tested experimental conditions, Aducanumab<sub>bs</sub> and 1E4E11 (<bold>Appendix 10</bold>) showed preference for Aβ peptide fragments phosphorylated at Ser(8) (pSer(8)). Donanemab<sub>bs</sub>, 2-48, and Aβ-pE3 exhibited high selectivity for Aβ peptides starting with an N-terminal pE (<xref rid="fig3" ref-type="fig">Figure 3D</xref>) over Aβ3-x starting with a non-cyclized Glu and other Aβ variants. In contrast, mAb IC16 showed weaker binding to AβpE3-x than to Aβ3-x. Abs 7H3D6 and 11H3 did not recognize Iso-Asp(1), while 11H3 interestingly showed no affinity for D-Asp(1)-modified Aβ peptides. As expected, all of the tested antibodies, which are directed against the N-terminal Aβ region, did not show appreciable binding, and only 5H11C10 bound to the phosphorylated Ser(26) when the modification was localized centrally within Aβ19-32 (<xref rid="fig3" ref-type="fig">Figure 3E, F</xref>).</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Multiplex Analysis of Aβ-Abs with preference for post-transcriptionally modified Aβ variants</title><p>The signals were normalized internally and presented as a heat map ranging from 0 to 1. Blue and red shades indicate the binding strength over the related arrayed post-transcriptionally modified peptide shown on top and cognate anti-Aβ antibody to the left. The antibodies were tested under optimal dilutions: 6E10, IC16, Aβ-pE3, 1E411, 101-1-1, 5H11C10, 2-48 at 0.25µg/mL; Lecanemab<sub>bs</sub>, Donanemab<sub>bs</sub> at 0,0012µg/mL; Aducanumab<sub>bs</sub> at 0.02µg/mL; 3D6, 11H3, 82E1 at 0.037 µg/mL; 7H3D6 at 0.012µg/mL. The dataset is split over different sections (a-f) to allow proper visualization. Each antibody was screened in parallel against all modifications. (a) The control peptide Aβ(-1-14) was used alongside Asp(1) isomers and stereoisomers. (b) The region overlapping with unmodified Serine 8. (c) The region overlapping with modified phospho Serine 8 (represented as ’2’). (d)Tthe control unmodified 3-17 was used alongside pE3. (e) The region overlapping with unmodified Serine 26. (f) The region overlapping with modified phospho Serine 26 (represented as ’2’).</p></caption>
<graphic xlink:href="640323v2_fig3.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2g">
<title>pSer8-Preference of Aducanumabbs in the Context of Non- Aggregated Aβ</title>
<p>Aducanumab has been reported to preferentially target aggregated Aβ [<xref ref-type="bibr" rid="c40">40</xref>] and bind monomeric Aβ with low micromolar affinity [<xref ref-type="bibr" rid="c41">41</xref>], tetrameric Aβ1-15 with low nanomolar affinity and aggregated Aβ with sub-nanomolar affinity corresponding to a roughly 10.000- fold enhanced affinity for Aβ aggregates [<xref ref-type="bibr" rid="c40">40</xref>,<xref ref-type="bibr" rid="c41">41</xref>]. However, in our hands, on microarray and under the tested experimental conditions, we observed appreciable binding of Aducanumab<sub>bs</sub> to short, monomeric Aβ-related peptides (<xref rid="fig1" ref-type="fig">Figures 1</xref><bold>, 2, 3</bold>), which we followed up by studying some molecular details. Prompted by the observed preference of Aducanumab<sub>bs</sub> for phosphorylated pSer8-Aβ(-1-14) and pSer8-Aβ1-15 over unphosphorylated Aβ-related 15- mers on our microarrays (<xref rid="fig3" ref-type="fig">Figure 3</xref>, <xref rid="fig3s2" ref-type="fig">Figure 3 - supplement 2A</xref>), we sought to quantify the underlying relative affinity differences using the purified epitope variants in BLI as a proof-of- concept experiment with the caveat that the assay may affect the absolute affinity due to multivalency and high-density effects. As a reference, mAb 1E4E11 was titrated over the immobilized phosphorylated Aβ variant (<xref rid="fig3s1" ref-type="fig">Figure 3 – figure supplement 1</xref>) (<bold>Appendix 9</bold>). As expected, mAb 1E4E11 showed a strong response in the nanomolar affinity range with fast on rates and very slow off rates, resulting in a K<sub>D</sub> of 4 nM. In contrast, the overall response was at least within an order of magnitude lower with the unphosphorylated peptide and showed fast off rates, resulting in a quantified K<sub>D</sub> of only 1.3μM for mAb1E4E11 binding. Overall, mAb 1E4E11 showed a 300-fold preference for the phosphorylated Aβ variant in this assay.</p>
<p>Henceforth, we applied this methodology to Aducanumab<sub>bs</sub> (<xref rid="fig3s2" ref-type="fig">Figure 3 – figure supplement 2</xref>) and observed a preference for monomeric Aβ1-15 phosphorylated at Ser(8) over unphosphorylated Aβ1-15. Initially, both modified and unmodified Aβ1-15 peptides were loaded onto the BLI sensors and tested with different antibody concentrations. The affinity for the phosphorylated variant was at least 6 times higher than for the unmodified peptide, however, on microarray, the EC50 for the pSer8-Aβ1-15 was 300 times lower than that for the corresponding unphosphorylated peptide (<bold>Appendix 10</bold>). Importantly, this was only detectable on semi-quantitative array analysis, which can be explained by multivalency effects that may lower the observed antibody off-rate. Overall, the affinity quantification in BLI did not result in a large difference between the two variants and we thus concluded that Aducanumab<sub>bs</sub> has agnostic preference for a negative charge, either provided by a carboxylic (Asp or Glu – see <xref rid="fig2" ref-type="fig">Figure 2</xref>) or phosphoserine group (<xref rid="fig3s2" ref-type="fig">Figure 3 – figure supplement 2</xref>), as it was not selective for the latter. This is in strong opposition to the state-of art pSer(8) antibody 1E4E11, which did not recognize phoshomimetic amino acid exchanges such as aspartate or glutamate (<xref rid="fig2" ref-type="fig">Figure 2</xref>). This observation raised the question of whether Aducanumab<sub>bs</sub> is involved in electrostatic interaction.</p>
<p>To further explore the relevance of the observed interaction between Aducanumab<sub>bs</sub> and the N- terminal phosphorylated Aβ fragment, we conducted molecular dynamics (MD) simulations (<xref rid="fig3s3" ref-type="fig">Figure 3 – figure supplement 3</xref>) using the published crystal structure of Aβ2-7 and Aducanumab Fab complex (PDB: 6CO3). These simulations were performed using Molecular Operating Environment (MOE) software. Specifically, we investigated two different short Aβ peptide sequences, <italic>AEFRHDS</italic> and <italic>AEFRHDpS</italic>, to examine how phosphorylation at Ser(8) affects the binding stability of the antibody-antigen complex.</p>
<p>By assuming that fewer fluctuations in the system correlate with a higher affinity, these data provide insights into the preferential binding mode of Aducanumab to phosphorylated short N- terminal Aβ fragments. By assuming that fewer fluctuations in the system lead to higher affinity, the root mean square deviation (RMSD) diagrams indicate greater stability (average conformation over 600ns) for the phosphorylated peptide due to its reduced fluctuations (<xref rid="fig3s3" ref-type="fig">Figure 3 – figure supplement 3</xref>). Additionally, the phospho group enhances the interaction with extra hydrogen bonds compared to the unmodified peptide (<xref rid="fig3s3" ref-type="fig">Figure 3 – figure supplement 3</xref>). Conversely, the non-phosphorylated peptide exhibits more fluctuations (<xref rid="fig3s3" ref-type="fig">Figure 3 – figure supplement 3</xref>). Thus, under these conditions, the MD simulation results confirm the findings from the microarray and BLI analyses.</p>
<p>Taken together, the MD simulations rationalize the unexpected preference of Aducanumab<sub>bs</sub> towards monovalent pSer8Aβ1-15 we observed on microarray. The observation underscores the complexity of Aducanumab<sub>bs</sub> binding to Aβ. This is further substantiated by comparing the previously resolved structure [<xref ref-type="bibr" rid="c41">41</xref>] with the MD simulation for short non-phosphorylated and pSer(8) Aβ-related peptides. Here, pSer8-Aβ2-8, unlike the corresponding non-phosphorylated Aβ, replicates the structurally determined binding mode. In the MD simulation, using the resolved epitope peptide EFRHDpS allows for the binding mode that has R317 and R318 contributing to the paratope. Similarly, the crystal structure (PDB 6CO3) includes a sulfate ion [<xref ref-type="bibr" rid="c41">41</xref>] that neutralizes the positive charges of R317 and R318 (<xref rid="fig3s4" ref-type="fig">Figure 3 – figure supplement 4</xref>). In summary, the monomeric binding mode benefits from the neutralization of a positive patch on Aducanumab Fab, which likely explains the phospho-preference.</p>
</sec>
<sec id="s2h">
<title>Immunoprecipitation with Synthetic and Endogenous Aβ-Peptides Highlights Context-Dependent Aβ-Abs Binding</title>
<p>Thus far, we showed that the initial microarray analysis proved invaluable in defining linear binding motifs, but needs to be complemented in different settings as more complex features of the binding behavior may be missed otherwise. In the following sections, we shift our focus to full-length Aβ peptides, which should reflect the conformations encountered <italic>in vivo</italic> and therefore provide insights into pathophysiologically relevant antibody binding. Thus, the screening results obtained with short Aβ fragments were next extended by analyses with intact Aβx-40 and x-42 variants. Here, the monoclonal Aβ-Abs 4G8, Donanemab<sub>bs</sub>, Lecanemab<sub>bs</sub>, Aducanumab<sub>bs</sub>, and 1E4E11 were tested as representative examples for their capacity in immunoprecipitating specific Aβ variants out of a mixture of ten synthetic Aβ peptides (<xref rid="fig4" ref-type="fig">Figure 4</xref>, <bold>Appendix 11-12</bold>). The mixture included Aβ1-40 and 1-42, N-terminal truncated Aβ(2-40, 3-40, pE3-40, 4-40, 5-40, 11-40), N-terminal elongated Aβ(-3-40) and phosphorylated pSer8- Aβ1-40 (amidated C-terminal carboxyl group). The antibodies were covalently coupled to magnetic beads and incubated, separately, with aliquots of the Aβ peptide mixture. After washing the magnetic bead immune complexes, the bound Aβ peptides were eluted, and the immunoprecipitated products were analyzed using MALDI-TOF-MS on TOPAC matrix (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). As previously established [<xref ref-type="bibr" rid="c82">82</xref>], the TOPAC matrix allows for improved detection of phosphorylated Aβ with minimal phosphate loss. Two control antibodies, 4G8 (core epitope 17-21 according to our microarray data) and 1E4E11, were used to set up the system, representing respectively, “pan-Abeta” and pSer8-Aβ1-40 profiles.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4:</label>
<caption><title>IP-MS signature of different biosimilar Aβ-Abs.</title>
<p><bold>(A)</bold> A mixture of synthetic Aβ peptides was immunoprecipitated with the following Aβ-Abs (from top to bottom): 4G8 (pan-antibody), Donanemab<sub>bs</sub> (Don-bs), Lecanemab<sub>bs</sub> (Lec-bs), Aducanumab<sub>bs</sub> (Adu-bs), and 1E4E11 (phospho-selective control). Mass spectra were generated by MALDI-TOF-MS in reflector mode from TOPAC matrix and are representative for two independent experiments. We noted that the signal pattern slightly varied between experiments, which we mainly attributed to some immunoprecipitation of co-aggregated Aβ species, an effect that has to be considered under the experimental conditions applied. (B) IP-MS from pooled human CSF using MALDI-TOF-MS from conventional CHCA matrix. Mab 4G8 (positive control) and Lecanemab<sub>bs</sub>, but not Aducanumab<sub>bs</sub> immunoprecipitated authentic biological Aβ peptides from pooled human CSF under the tested conditions. Major peaks were observed for Aβ1-40 and Aβ1-38. The spectra shown are representative for two replicate measurements each from two independent immunoprecipitations.</p></caption>
<graphic xlink:href="640323v2_fig4.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>The IP-MS signature of 4G8, after incubation with the 10 peptide mix, showed signals from all constituents thus acting as positive control, with major intensities for Aβ5-40, intermediate signals for Aβ4-40, Aβ3-40, Aβ2-40, and Aβ1-40, and only minor signals for Aβ1-42, Aβ(-3- 40) and pSer8 Aβ1-40 (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). Additionally, pyroglutamate AβpE3-40 was clearly recognized by mAb 4G8. As expected from its central epitope 17-21, 4G8 was the only Ab that showed an intense signal for N-terminally truncated Aβ11-40. The monoclonal antibody 1E4E11 preferentially precipitated pSer8-Aβ1-40-amide and, additionally, Aβ2-40, Aβ1-42 and Aβ1-40. The phosphorylated pSer8-Aβ1-40-amide produced the highest signal, suggesting a certain degree of preference (but not specificity) of 1E4E11 for phosphorylated pSer8-Aβ- amide under the tested conditions (<xref rid="fig4" ref-type="fig">Figure 4A</xref>).</p>
<p>In line with the PTM-microarray screening (<xref rid="fig3" ref-type="fig">Figure 3</xref>), Donanemab<sub>bs</sub> exhibited highly preferential binding to AβpE3-40, with only minor signals for Aβ3-40 and Aβ2-40 (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). The IP-MS spectra obtained with Lecanemab<sub>bs</sub> showed predominant peaks for Aβ2-40, Aβ1-42, and Aβ1-40 in line with the apparent location of the epitope in the N-terminal region of Aβ (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). However, synthetic Aβ peptides may display different properties than authentic Aβ peptides in biological samples, such as human cerebrospinal fluid (CSF). Importantly, Lecanemab was previously shown to have a strong preference for Aβ protofibrils and to bind Aβ monomers only weakly [<xref ref-type="bibr" rid="c83">83</xref>]. To test whether Lecanemab<sub>bs</sub> was able to immunoprecipitate endogenous soluble Aβ from a relevant biological sample, we repeated the Lecanemab<sub>bs</sub> IP-MS experiment with 250 µL of pooled CSF. In the resulting IP-MS spectrum, Aβ1-40, Aβ1-38, Aβ42, Aβ1-37 and Aβ1-39 were detected, albeit with relatively low signal intensities (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). IP-MS from pooled CSF with Aducanumab<sub>bs</sub> did not produce any Aβ signals (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). In contrast, using the mix of ten synthetic Aβ peptides for Aducanumab<sub>bs</sub> magnetic bead IP, we observed clear signals for Aβ2-40, Aβ1-42, Aβ1-40, but not for phosphorylated pSer8-Aβ1-40-amide (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). This was in contrast to the binding data from array and BLI towards the minimal monovalent epitopes (<xref rid="fig3s2" ref-type="fig">Figure 3 – figure supplement 2</xref> and <xref rid="fig3s3" ref-type="fig">3</xref>.</p>
<p>For Aducanumab<sub>bs</sub>, microarray, BLI and IP-MS data suggest three binding modes. One presumably aggregation specific site (<italic>EFRHDS</italic>) as predicted by previous molecular dynamics studies [<xref ref-type="bibr" rid="c84">84</xref>], primarily via neutral V<sub>L</sub>, where the Ser(8) would only contact the Tyr-92 [<xref ref-type="bibr" rid="c84">84</xref>], in line with previous data [<xref ref-type="bibr" rid="c41">41</xref>]. A second binding site (EFRHDpS) relevant for the binding of short synthetic N-terminal Aβ fragments as resolved by our pSer(8) MD primarily contacting the positively charged V<sub>H</sub> chain paratope via Arg-317-318 and in agreement with the sulfate ion-containing structure (<xref rid="fig3s4" ref-type="fig">Figure 3 – figure supplement 4</xref>). Lastly, in a similar way the binding of Aducanumab to monomeric A<italic>EFRHDS</italic> (Aβ2-8) can benefit from the presence of negatively charged sulfate ions [<xref ref-type="bibr" rid="c41">41</xref>] (pdb: 6CO3). Of note, a recent molecular dynamics study suggested the presence of an N-terminal neutral domain in Aβ protofibrils (Aβ:Fab contact Ser8:Tyr92) [<xref ref-type="bibr" rid="c34">34</xref>], which may contribute for the preferential binding of Aducanumab to aggregated forms of Aβ.</p>
</sec>
<sec id="s2i">
<title>Aggregation-Dependent Binding of Biosimilar Aβ-Abs in vitro and in AD brain tissue</title>
<p>To further complement the characterization of the biosimilar Aβ-Abs, we applied gel electrophoretic separations of Aβ peptides followed by Western blotting, automated Capillary Isoelectric Focusing immunoassays (CIEF-immunoassay) with charge-based separation of Aβ peptides, and immunohistochemistry (IHC) experiments on brain tissue with pre-adsorption of Aβ-Abs.</p>
<p>Aducanumab and Lecanemab preferably bind specific aggregated forms of Aβ over monomeric forms [<xref ref-type="bibr" rid="c38">38</xref>,<xref ref-type="bibr" rid="c40">40</xref>,<xref ref-type="bibr" rid="c41">41</xref>][<xref ref-type="bibr" rid="c38">38</xref>,<xref ref-type="bibr" rid="c83">83</xref>]. In agreement with these reports, our analysis showed that Aducanumab<sub>bs</sub> clearly detected highly aggregated fibrillar Aβ1-42 on Bistris-SDS gradient PAGE/Western blot. In contrast, it generated essentially no appreciable signals with monomerized hexafluoroisopropanol (HFIP)-treated or oligomeric Aβ1-42 preparations under the tested conditions (<xref rid="fig5" ref-type="fig">Figure 5A</xref>). On peptide Bicine-Tris SDS-PAGE/Western blot and on CIEF-immunoassays we observed substantial variances with Aducanumab<sub>bs</sub> between different experiments (data not shown), making reliable interpretations difficult [<xref ref-type="bibr" rid="c85">85</xref>]. The observed high variance of the Aducanumab<sub>bs</sub> results on CIEF-immunoassay and peptide SDS-PAGE/Western blot might be related to the low affinity of Aducanumab for monomeric Aβ [<xref ref-type="bibr" rid="c41">41</xref>] and the possibility that Aβ dimers or low order oligomers might form during the experiment [<xref ref-type="bibr" rid="c85">85</xref>]. In good agreement with the strong preference of Aducanumab<sub>bs</sub> for highly aggregated fibrillar Aβ (see above), pre-adsorption with fibrillar Aβ1-42 largely blocked Aducanumab<sub>bs</sub> immunoreactivity of vascular and parenchymal Aβ deposits in AD brain tissue, in contrast to pre-adsorption with an excess of Aβ1-42 monomers (<xref rid="fig5" ref-type="fig">Figure 5B</xref>).</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5:</label>
<caption><title>Aducanumab<sub>bs</sub> shows strong preference for highly aggregated fibrillar Aβ1-42.</title><p>(A) HFIP-treated Aβ1-42 monomer (m), oligomer (o) and fibril preparations (f) (1.44 µg each) were separated by 4-12% Bistris SDS-PAGE, blotted onto nitrocellulose and probed with Aducanumab<sub>bs</sub> (5 min exposure, F 0.84, image display: High: 65535; Low: 0; Gamma: 0.85). Following image recording the blot membrane was reprobed without prior stripping (no removal of primary and secondary antibodies) with mAb4G8 (1 min exposure, image display: High: 54971; Low: 0; Gamma: 0.99). That way the 4G8 signals were essentially added on top of the initial Aducanumab<sub>bs</sub> signals and background artifacts. The positions of pre-stained protein marker bands on the blot membrane are shown on the left-hand side. (B) Parallel sections from an AD patient were stained with Aducanumab<sub>bs</sub> and Aducanumab<sub>bs</sub> that had been pre-adsorbed with either Aβ1-42 monomers (Aβ1-42m) or Aβ1-42 fibrils (Aβ1-42f). Scale bar: 200 µm.</p></caption>
<graphic xlink:href="640323v2_fig5.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Lecanemab<sub>bs</sub> recognized Aβ1-40, Aβ1-42, Aβ3-40 (pI approximately 5.97) Aβ-3-40 (aka. APP669-711),phosphorylated pSer8-Aβ1-40on CIEF-immunoassay and Bicine-Tris SDS- PAGE/ Western blot, thus recapitulating the initial microarray mapping for Lecanemab<sub>bs</sub> shown in <xref rid="fig1" ref-type="fig">Figure 1</xref>. It appears, that under these experimental conditions Lecanemab<sub>bs</sub> can bind to an epitope located in the N-terminal region of the Aβ sequence. On gradient Bistris SDS- PAGE/Western blot and under the tested conditions, Lecanemab<sub>bs</sub> showed a certain, but not absolute preference for aggregated forms of Aβ1-42 over monomeric and low-n oligomeric forms in the HFIP-treated Aβ1-42 preparation (<xref rid="fig6" ref-type="fig">Figure 6</xref>). The immunohistochemical detection of Aβ in vascular and parenchymal deposits by Lecanemab<sub>bs</sub> in brain sections from an AD- patient was efficiently blocked by antibody pre-adsorption with monomerized, oligomeric and fibrillar preparations of Aβ1-42 (<xref rid="fig6" ref-type="fig">Figure 6E</xref>). However, it cannot be excluded, that the HFIP treated Aβ1-42 monomers aggregated during the experiment.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6:</label>
<caption><title>Lecanemab<sub>bs</sub> recognizes an epitope located in the N-terminal region.</title>
<p>(A) shows an example of CIEF-immunoassay results for Lecanemab<sub>bs</sub> displayed as lane view (Western blot simulation). The indicated Aβ peptides were separated by isoelectric focusing in microcapillaries on a Peggy Sue device, immobilized photochemically to the inner capillary wall and subjected to immunological detection. Under the tested conditions, Lecanemab<sub>bs</sub> detected Aβ1-40 (pI 5.31), Aβ2-40 (pI 5.98), Aβ3-40 (pI 5.97), Aβ-3-40 (pI 6.04), Aβ1-42 (pI approx. 5.3) and pSer8Aβ1-40 (amide) (pI 5.13-5.14). (B) Synthetic Aβ2-40 (361 ng), and monomerized (m), oligomeric (o) and fibrillar (f) preparations of Aβ1-42 (361 ng of each) were separated by 4-12% Bistris SDS-PAGE, blotted onto nitrocellulose and probed with Lecanemab<sub>bs</sub> (0.5 µg/mL). Exposure: 2 min 7.5 sec; F 0.84; image display: high: 47545; low: 0; gamma: 1.0. After blot development, the blot membrane was reprobed with mAb 4G8 without prior stripping. That way the 4G8 signals were essentially added on top of the initial Lecanemab<sub>bs</sub> signals and background artifacts. Exposure: 1 min F 0.84; image display: high: 46277; low: 0; gamma: 1.0. (C) The indicated Aβ peptides (50 ng of each) were separated by Bicine Tris (peptide) SDS-PAGE, blotted on PVDF, and probed with Lecanemab<sub>bs</sub>. Exposure: 5 min F 0.84, image display: high: 65535; low: 0; gamma: 0.85. (D) To confirm loading and successful blotting of all Aβ peptides, the blot membrane was re-probed with mAb 4G8 without prior stripping (see above). Exposure: 5 min F 0.84; image display: high: 65535; low: 0; gamma: 1.0. (E) Parallel sections from an AD patient were stained with Lecanemab<sub>bs</sub> and Lecanemab<sub>bs</sub> that had been pre-adsorbed with either Aβ1-42 monomers (Aβ1-42m), Aβ1-42 oligomers (Aβ1-42o) or Aβ1-42 fibrils (Aβ1-42f). Scale bar: 200 µm.</p></caption>
<graphic xlink:href="640323v2_fig6.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2j">
<title>C-Terminal Aβ Elements Contribute to Lecanemab-Binding in Tissue</title>
<p>To investigate in more detail the dependence of Lecanemab<sub>bs</sub> binding on the Aβ peptide length and presumed resulting conformational differences, we performed additional pre-adsorption assays using a series of C-terminal truncated Aβ peptides with an intact N-terminal epitope. Since the original Lecanemab biosimilar antibody (Proteogenix Cat. No PX-TA1746) was not available anymore, Lecanemab<sub>bs</sub> obtained from a different source (BioXCell (#BXC-SIM0032/ InVivoSIM) was used. Again, preincubation with Aβ1-42 monomers (Stressmarq) completely blocked Lecanemab<sub>bs</sub> binding, whereas shorter peptides such as Aβ1-16, Aβ1-34 and Aβ1-38 did not. Thus, it appears that an intact N-terminus alone is not sufficient for Lecanemab<sub>bs</sub> recognition, suggesting that additional elements contribute to Lecanemab binding of oligomers and aggregates.</p>
<p>On CIEF-immunoassay and Bicine-Tris SDS-PAGE/Western blot, Donanemab<sub>bs</sub> detected AβpE3-40 and Aβ3-40 (both at a pI of approximately 5.95 on CIEF immunoassay) with a clear preference for the Aβ variant starting with the cyclized N-terminal pE. Other N-terminal Aβ variants that were tested produced no or very small signals (<xref rid="fig7" ref-type="fig">Figure 7 B, C</xref>). On gradient Bistris SDS-PAGE/Western Blot, Donanemab<sub>bs</sub> detected multiple AβpE3-40 bands in the low Mwrange, presumably representing monomers and low order oligomers which were formed during sample preparation or SDS electrophoresis [<xref ref-type="bibr" rid="c85">85</xref>]. The HFIP-treated monomeric, oligomeric and fibrillar Aβ1-42 preparations produced very faint signals with Donanemab<sub>bs</sub> (<xref rid="fig7" ref-type="fig">Figure 7D</xref>). Re-probing of the blot (without stripping) with mAb4G8 showed multiple Aβ1- 42 bands in the low molecular weight range (&lt;15 kDa) in the HFIP-treated preparation (presumably monomers and low order oligomers). The Aβ1-42 oligomer preparation showed a similar pattern of bands smaller than 15 kDa and between 25 and 100 kDa. The Aβ1-42 fibril preparation showed low order oligomeric Aβ1-42 bands, in the molecular weight range of 37.5 to 150 kDa as well as highly aggregated Aβ1-42 which, unable to enter the stacking gel. On immunohistochemistry, the detection of Aβ vascular and parenchymal deposits by Donanemab<sub>bs</sub> in AD brain sections was efficiently suppressed by pre-adsorption of the antibody with synthetic AβpE3-40, but not with Aβ1-40 or Aβ3-40 peptides (<xref rid="fig7" ref-type="fig">Figure 7E</xref>).</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Figure 7:</label>
<caption><title>Donanemab<sub>bs</sub> shows high preference for pyroglutamate bearing pEAβ3-40.</title>
<p>The upper panel shows lane views (Western blots simulation) of a CIEF-immunoassay for assessing the detection of different Aβ variants by (A) mAb 4G8 (positive control antibody) and (B) Donanemab<sub>bs</sub>. The indicated Aβ variants were separated by isoelectric focusing in microcapillaries on a Peggy-Sue device, immobilized photochemically to the inner capillary wall and subjected to immunological detection by (A) mAb 4G8 and (B) Donanemab<sub>bs</sub>. (C) Synthetic Aβ peptides (50 ng per lane) were separated by Bicine Tris (peptide) SDS-PAGE, blotted on PVDF and probed with Donanemab<sub>bs</sub> (0.5 µg/mL) (upper image). Exposure: 5 min F 0.84; image display: high: 59406; low: 0; Gamma: 0.65. To confirm that all Aβ variants were loaded and blotted, the blot membrane was reprobed with mAb 4G8 without prior stripping. That way, the 4G8 signals were essentially added on top of the initial Donanemab<sub>bs</sub> signals and background artifacts (lower image). Exposure: 5 min F 0.84; image display: high: 65535; low: 0; gamma: 0.77. (D) AβpE3-40 and Aβ1-42 monomer (m), oligomer (o) and fibril preparations (f) were separated by 4-12% Bistris SDS-PAGE, blotted onto nitrocellulose and probed with Donanemab<sub>bs</sub> (image display: High: 64091; Low: 0; Gamma: 0.75), followed by reprobing without prior stripping with mAb4G8 (image display: High: 46984; Low: 0; Gamma: 1.0). The positions of prestained protein marker bands on the blot membrane are shown on the left-hand side. (E) A pre-adsorption experiment employing synthetic Aβ peptides in human AD brain tissue showed that the immunoreactivity of Donanemab<sub>bs</sub> was not suppressed by pre-adsorption of the antibody with excess amounts of synthetic Aβ1-40 and Aβ3-40 peptides. In contrast, a pre-incubation with AβpE3-40 effectively attenuated the antibody signal in extracellular Aβ deposits as well as in the vasculature.</p></caption>
<graphic xlink:href="640323v2_fig7.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Conclusion</title>
<p>The exact binding specificity of Aβ-Abs, and its dependence on sequence context and aggregation state, is central both for their use as research tools and for their evaluation and development as therapeutic and diagnostic agents. Here we combined high-density peptide microarray analysis with complementary methodologies to generate a comprehensive dataset for 20 research and biosimilar Aβ-Abs. In total, 20,000 peptide–antibody interactions resolved individual epitopes at single–amino-acid resolution and clarifying the influence of PTMs and amino-acid exchanges for all epitopes within a unified experimental setup. The array analyses were complemented by IP-MS, CIEF immunoassay, SDS-PAGE/Western blot, and immunohistochemistry studies, thereby linking fine epitope definition and profiling with binding of full-length Aβ under native and aggregated conditions.</p>
<p>Comparative analyses highlighted clear mechanistic differences between the three therapeutic antibodies. For Donanemab, screening of monovalent peptides consistently recapitulated a core epitope at residues 3–10, with cyclized AβpE3-x as the dominant binding determinant. In contrast, Lecanemab and Aducanumab both required aggregated Aβ for full binding activity but mapped to overlapping N-terminal sequences (residues 3–7 for Lecanemab; 2–7 for Aducanumab). Binding quantification further substantiated a preference of Aducanumab for Ser8-phosphorylated Aβ for non-aggregated forms, and a marked sensitivity to the familial H6R mutation, consistent with recent reports linking antibody efficacy to differences between soluble and aggregated Aβ pools [<xref ref-type="bibr" rid="c86">86</xref>]</p>
<p>The qualitative and quantitative binding data, together with our molecular dynamics simulations and the previous structural reports, provide a mechanistic explanation for the observed binding requirements. For Aducanumab, X-ray crystallography revealed a Fc- mediated dimer interface that stabilises binding to aggregated Aβ [<xref ref-type="bibr" rid="c41">41</xref>]. This dimerisation also explains our observed preference for pSer8-modified Aβ monomers: phosphorylation neutralises the Arg-Ala-Arg motif at the Fc-dimer interface, thereby promoting dimerisation and avidity-enhanced binding. In aggregated Aβ forms, such phosphorylation is dispensable because avidity is already provided by multimerisation, reconciling our peptide library, BLI, and tissue binding results with structural models and simulations of Aducanumab [41, [<xref ref-type="bibr" rid="c84">84</xref>],93]. For Lecanemab, our binding profiles align closely with the model proposed on the basis of D3 antibody similarity (PDB 5MY4) [<xref ref-type="bibr" rid="c93">93</xref>], correctly accounting for sequence tolerances at positions 3–7. However, in contrast to published claims [<xref ref-type="bibr" rid="c93">93</xref>], we find no evidence that N- terminal extensions beyond Glu3 reduce affinity. Binding is preserved both in vitro and in AD tissue, supporting a minimal epitope definition that includes residues 3–7, consistent with our peptide, MS, and immunohistochemistry data [<xref ref-type="bibr" rid="c38">38</xref>,<xref ref-type="bibr" rid="c93">93</xref>], and with recent demonstrations of Lecanemab’s preferential binding to fibrillar Aβ aggregates [<xref ref-type="bibr" rid="c46">46</xref>].</p>
<p>In summary, we systematically compared the binding requirements of 20 Aβ-Abs, addressing sequence (including genetic and species variants), PTM, and structural aspects. By resolving discrepancies between structural models and biochemical data, we provide mechanistic insight into the distinct binding modes of Aducanumab and Lecanemab, and into the strict selectivity of Donanemab. This work provides a resource for the rational selection of Aβ-Abs in research and diagnostics and may help inform the evaluation and design of future therapeutic and diagnostic Aβ-Abs.</p>
</sec>
<sec id="s4">
<title>Methods</title>
<sec id="s4a" sec-type="ethics-statement">
<title>Ethics approval and patients consent</title>
<p>In this study, a pooled CSF sample prepared from several individual CSF samples from the local biobank at the Department of Psychiatry and Psychotherapy at the University Medical Center Göttingen was used in some IP-MS experiments. The collection and archiving of biological samples and clinical data in strictly pseudonymous form in a local biobank and their use in biomarker research were approved by the ethics committee of the University Goettingen (Protocol number 9/2/16). From all participants or their legal representatives written informed consent was obtained prior to the inclusion in the biobank. All study participants received detailed information prior to enrolment in the study and collection of the biomaterial. In addition, an information sheet was handed out by the study physicians at the Department of Psychiatry and Psychotherapy at the University Medical Center Göttingen. After a possible reflection period, written informed consent was obtained from the study participants. If the ability to consent was not given, a separate informed consent form was also provided for the study participant’s legal representative, and the legal representative signed the informed consent form for the study. All procedures involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p>
<p>Paraffin-embedded human brain samples from individuals with sporadic Alzheimer’s disease (AD) were obtained from the Netherlands Brain Bank (NBB,Netherlands Institute for Neuroscience, Amsterdam (open access: <ext-link ext-link-type="uri" xlink:href="https://www.brainbank.nl">www.brainbank.nl</ext-link>)). All material has been collected from donors for or from whom a written informed consent for a brain autopsy and the use of material and clinical information for research purposes had been obtained by the NBB. For the -analyses in the present study, sections from the medial frontal gyrus region of the brain were utilized. All procedures involving human tissue were approved by the ethical committee at the University Medical Center Göttingen (Protocol number 12/1/15).</p>
</sec>
<sec id="s4b">
<title>Preparation of Functionalized Cellulose Discs</title>
<p>Paper functionalization was performed by introducing some variations to the previous protocol [<xref ref-type="bibr" rid="c87">87</xref>] aimed at increasing the output of discs per session. In brief, Whatman paper grade 50 (45 × 25 cm) was cut into 4mm diameter discs using an OMTech 50-watt CO2 laser at 7.8% power and 150 mm/s speed. To reduce mechanical stress and facilitate transfer into a 384-plate, each disc was cut with a semi-circular pattern. The pre-cut layout (15 x 10 cm) was then treated for 3 hours with a solution of 9-fluorenylmethyloxycarbonyl-β-alanine (Fmoc-β-Ala-OH), diisopropylmethanediimine (DIC) and 1-Methylimidazole (NMI). The Fmoc absorption of each batch of functionalized cellulose membrane was determined at 290nm after 20 minutes of deprotection with 20% (v/v) piperidine (pip) in DMF. The average loading was 130nmol/disc.</p>
</sec>
<sec id="s4c">
<title>Microarray Synthesis</title>
<p>The µSPOT assay was performed as previously described [<xref ref-type="bibr" rid="c88">88</xref>]. First, the APP sequence (UniProtKB: P05067) was displayed in microarray format as 15mer overlapping peptide library. Peptide arrays were synthesized [<xref ref-type="bibr" rid="c89">89</xref>–<xref ref-type="bibr" rid="c91">91</xref>] using MultiPep RSi robot (CEM GmbH, Kamp-Lintford, Germany) on cellulose discs containing Fmoc-β-Ala linkers. Natural amino acid building blocks were purchased from IRIS (IRIS Biotech GmbH, Marktredwitz, Germany). Special building blocks employed in this study such as isomers, stereoisomers, phosphorylation and pyroglutamination post-transcriptional modifications are listed here: Fmoc-L-Ser(PO(OBzl)OH)-OH (Iris – FAA1423), L-Pyroglutamic acid pentachlorophenyl ester (Novabiochem - 8.54203), Fmoc-L-Asp-OtBu (Iris – FAA1356), Fmoc-D-Asp-OtBu (Carbosolutions – CC05095) and Fmoc-D-Asp(tBu)-OH (Iris – FAA1309). Synthesis was carried out by deprotecting the Fmoc-group using 20% piperidine in dimethylformamide (DMF). Peptide chains were elongated using a coupling solution consisting of amino acids (0.5M) with oxyma (1M) and DIC (1M) in DMF (1:1:1). Coupling steps were carried out 3 times (30min), followed by capping (4% acetic anhydride in DMF). Discs were transferred into 96 deep-well plates for the work-up. Side chains were deprotected using 90% trifluoracetic acid (TFA), 2% dichloromethane (DCM), 5% H<sub>2</sub>O and 3% triisopropylsilane (150μL/well) for 1h at room temperature (RT). Afterward, the deprotection solution was removed, and the discs were solubilized ON at RT, while shaking, using a solvation mixture containing 88.5% TFA, 4% trifluoromethanesulfonic acid (TFMSA), 5% H2O and 2.5% TIPS (250μL/well). The resulting peptide-cellulose conjugates (PCCs) were precipitated with ice-cold ether (700μL/well) and spun down at 2000×g for 10min at 4°C, followed by two additional washes of the formed pellet with ice-cold ether. The resulting pellets were dissolved in DMSO (250μL/well).</p>
</sec>
<sec id="s4d">
<title>Microarray Quality Control</title>
<p>LC-MS was carried out using peptide quality controls that were cleaved from solid support. To ensure cleavage, a Rink amide linker (Iris) suitable for SPPS on cellulose support was introduced during the first coupling cycle. In an acidic environment, the quality controls were cleaved off from the solid support. To isolate the quality controls, 150 µL of the supernatant (SN) was transferred to 1.5 mL reaction tubes, followed by the addition of 700 µL of diethyl ether. The samples were then vortexed, and the peptides were allowed to precipitate by incubation at -20°C overnight. After centrifugation at 13,300 × g and 4°C for 10 min, the SN was discarded, and 500 µL of diethyl ether was added. The mixture was vortexed, centrifuged for 10 min, and the supernatant was decanted. This process was repeated twice, and the peptides were left to dry for 60 min. Finally, the Rink amides were dissolved in 50 µL of 50% acetonitrile: 0.1% formic acid (v/v) and vortexed briefly before centrifugation at 13,300 × g and room temperature. For analysis, the quality controls were diluted 1:3 and sent to LC-MS (Agilent technologies).</p>
</sec>
<sec id="s4e">
<title>Microarray Printing</title>
<p>PCCs solutions were mixed 2:1 with saline–sodium citrate buffer (150mM NaCl, 15mM trisodium citrate, pH7.0) and transferred to a 384-well plate. For transfer of the PCC solutions to white-coated CelluSpot blank slides (76×26mm, Intavis AG Peptide Services GmbH and CO. KG), a SlideSpotter (CEM GmbH) was used. After completion of the printing procedure, slides were left to dry ON.</p>
</sec>
<sec id="s4f">
<title>Microarray Binding Assay</title>
<p>The microarray slides were blocked for 60min in 5% (w/v) skimmed milk powder (Carl Roth) 0.05% Tween20 phosphate-buffered saline (PBS; 137mM NaCl, 2.7mM KCl, 10mM Na<sub>2</sub>HPO<sub>4</sub>, 1.8mM KH<sub>2</sub>PO<sub>4</sub>, pH7.4). After blocking, the slides were incubated for 30 min with a solution of blocking buffer and monoclonal and polyclonal Aβ-Ab (<xref rid="tbl1" ref-type="table">Table 1</xref>). They were then washed 3× with PBS 0.05% Tween20 for 1min. IgG antibodies were detected using goat anti mouse IgG-HRP (Thermo Fisher Cat. No31430), Goat anti-Rabbit IgG, Antibody, HRP (Cell Signaling: 7074), Goat anti-Rat IgG (H+L) Secondary Antibody, HRP (TF: 31470) and Goat anti-Human IgG (H+L) Secondary Antibody, HRP (TF: 31410). The chemiluminescence readout was detected with an Azure imaging system c400 (lowest sensitivity, 1s, 5s, 10s, 30s, 1m, 2m) using SuperSignal West Femto maximum sensitive substrate (Thermo Scientific GmbH, Schwerte, Germany). The raw grayscale intensities were measured using open-source MARTin software [<xref ref-type="bibr" rid="c92">92</xref>].</p>
</sec>
<sec id="s4g">
<title>Dot Blot</title>
<p>The purified peptides were printed onto white-coated CelluSpot blank slides using the Slide Spotter at a starting amount of 0.05 µg. The slides were allowed to dry for 3 hours and rinsed once with 1X PBS to remove the unbound peptides. After blocking in 5% (w/v) skimmed milk powder for 1 hour, the slides were incubated with 1nM Aducanumab<sub>bs</sub> and IgG signals were detected using goat anti-human IgG DL650 (1:1000 - Invitrogen 84545). The fluorescence signal readouts were acquired using Amersham Image Quant 800 (GE Healthcare) with an exposure time of 30 seconds and 4x4 binning.</p>
</sec>
<sec id="s4h">
<title>Molecular Dynamics Simulations</title>
<p>For molecular dynamic (MD) simulations the crystal structure of the aducanumab Aβ complex structure (PDB: 6CO3) was used. The complex structure was prepared using MOE (Molecular Operating Environment, 2022.02, Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A2R7, 2023) structure preparation tools with default values. For producing the MD-starting structure the experimentally resolved residues of the Aβ were prolonged by either a serine or a phosphorylated serine in MOE.</p>
<p>The MD simulations were conducted using AMBER22 suite [<xref ref-type="bibr" rid="c93">93</xref>]. Topology and parameter files were generated in tleap module using the AMBER ff14sb. The simulations were set up in the following way: The peptide-aducanumab complex was energy minimized for 2000 steps using a generalized Born implicit solvent model, neutralized, and solvated using the TIP3P water model. The system was equilibrated by heating the solvent from 100 K to 300 K within 500 ps under constant volume conditions with non-solvent atoms assigned with harmonic constraints of 100 kcal·mol-1·Å-2. Cooling the system back to 100 K within 250 ps and lowering the harmonic constraints on non-solvent atoms to 1 kcal·mol-1·Å-2, followed by heating to 300 K within 500 ps period. Afterwards, the non-solvent atoms constraints were set off and the pressure was adjusted to 1 bar using the Berendsen barostat. Each complex (unmodified and phosphorylated) was simulated in triplicates for 200 ns at constant pressure and temperature. All simulations were carried out using periodic boundary and particle mesh Ewald (PME) methodology to handle long-range electrostatics. 2 fs-time steps were used for integration and coordinates of were saved every 500 steps (1 ps). The trajectories were further analysed with CPPTRAJ (4.14.0).</p>
</sec>
<sec id="s4i">
<title>Aβ-Peptides for SDS-PAGE, CIEF Immunoassay and IP-MS</title>
<p>The synthetic peptides Aβ1–40, Aβ1–42, Aβ2–40, Aβ3–40, AβpE3–40, Aβ4–40, Aβ5–40 and Aβ11–40 were obtained from AnaSpec (Fremont, California, USA 94555). . Synthetic Aβ−3– 40 [<xref ref-type="bibr" rid="c94">94</xref>]was kindly provided by H.-J. Knölker, Technische Universität Dresden. Phosphorylated pSer8-Aβ1-40 was synthesized with an amidated C-terminal carboxyl group to remove one negative charge, ensuring that this Aβ variant still falls into the applied separation range of the CIEF immunoassay.</p>
</sec>
<sec id="s4j">
<title>Bistris-SDS Gradient PAGE/Western Blots Analysis of Different <bold>Aβ Aggregation States</bold></title>
<p>For the assessment of antibody binding to different Aβ aggregation states, we used Aβ1-42 monomers (Cat. No SPR-485B), Aβ1-42 oligomers (Cat. No SPR-488B) and preformed Aβ1- 42 fibrils (Cat. No SPR-487B) (StressMarq biosciences, Victoria, BC, Canada). The samples for electrophoresis were prepared (starting from stock solutions) with final concentrations of 0.1 µg/µL) in LDS sample buffer (247.5 mM Tris-HCl, pH 8.5, 2% (w/v) lithium dodecyl sulfate (LDS), 10% (v/v) glycerol, 0.5 mM EDTA, 0.22 mM Brilliant Blue G250, 0.175 mM Phenol Red) and denatured by heating at 70°C for 10 min. Per lane, 0.361, 0.722 or 1.44 µg of the different Aβ1-42 forms were loaded on a 4-12% Bistris-gel (1mm, 12 wells, Anamed Electrophorese GmbH, Groß-Bieberau / Rodau, Germany) and separated at 200 V using MES- SDS running buffer. Following recommendations provided by the manufacturer of the different Aβ1-42 aggregation forms, electroblotting onto nitrocellulose was done at 100 V for 1 hour with a Biorad mini tank blot. The prechilled transfer buffer contained 25 mM Tris, 192 mM glycine, 20% (v/v) methanol and 0.0375 % Tween-20. After blotting, the membrane was washed for 10 min at room temperature in Tris-buffered saline (TBS) followed by blocking for 30 min with 5% powdered milk in TBS containing 0.1% Tween-20 (TBS-T). The blots were then incubated with primary antibodies in 5% milk in TBS-T over night at 4°C and washed 3 x for 10 min with TBS-T at room temperature. The secondary antibodies were (i) Peroxidase- conjugated Affini Pure Donkey Anti-Human IgG (H+L), Jackons ImmunoResearch Laboratories Inc., West Grove, PA, (code number 709-035-149)1:20000 in TBS-T for Donanemab<sub>bs</sub>, Lecanemab<sub>bs</sub> and Aducanumab<sub>bs</sub> and (ii) anti-mouse IgG-POD (Calbiochem/EMD Millipore, San Diego, California, USA, catalog number 401253-2ML) 1:10000 in TBS-T for mAb 1E4E11 and mAb 6E10. After 1 h incubation with the secondary antibodies, the blots were washed 3 x for 10 min with TBS-T and incubated for 5 min with ECL-Prime Western Blotting Detection Reagent (Cytiva Amersham, Little Chalfont, England). Images were recorded on a Vilber-Loumart Fusion SL blot imager. To confirm successful blotting of all Aβ variants, the blot membranes were reprobed without prior stripping with mAb4G8 (0.5 µg/mL in 5% milk in TBS-T over night at 4°C or 1-2 h at room temperature) followed by anti-mouse IgG-POD (1:10000 in TBS-T) for 1 h at room temperature. That way, the 4G8 reprobing signals were essentially added on top of the initial signals and background artifacts.</p>
</sec>
<sec id="s4k">
<title>Peptide Bicine-Tris SDS-PAGE / Western Blot</title>
<p>Synthetic Aβ peptides were separated by 15% T/5% C Bicine-Tris SDS-PAGE, essentially according to[<xref ref-type="bibr" rid="c95">95</xref>]. After the electrophoresis, the gel was shortly rinsed with 50 mM Tris –HCl, pH 8.0, followed by blotting the peptides on PVDF using a Gravity Blotter (Serva Electrophoresis GmbH, Heidelberg, Germany). The blotting sandwich was assembled on the Gravity blotter from bottom to top by first placing the gel on the lower plate, followed by a precut PVDF membrane (activated with methanol and equilibrated in 50 mM Tris-HCl, pH 8.0), one filter paper Whatmann 3mM equilibrated in 50 mM Tris-HCl, pH 8.0, three dry filter papers (Sartorius BF4 blotting paper) and, finally, three 2.25 kg Gravity Blotter metal plates. The gravity/press blotting was done overnight at room temperature. On the next morning, the blot sandwich was disassembled and the PVDF membrane was boiled in PBS for 3min in a microwave oven with the protein side facing downwards. After blocking for 30 min at room temperature with 2% ECL Prime blocking reagent (Cytiva) in PBS containing 0.075% Tween- 20 (PBS-T), the blots were incubated for 1 h at room temperature with the primary antibodies (0.5 µg/mL in 2% ECL-Prime Western Blotting Detection Reagent in PBS-T). After 3 x 10 min washing with PBS-T, the secondary peroxidase-conjugated Affini Pure Donkey Anti- Human IgG (see above) (1:20000 in PBS-T) was applied for 1-2 hours at room temperature. Following 3 x 10 min washing with PBS-T, the blots were incubated for 5 min with ECL-Prime Western Blot Detection Reagent, and images were recorded. To confirm successful blotting of all Aβ variants, the blot membranes were reprobed without prior stripping with mAb4G8 (0.5 µg/mL in 2% ECL Prime blocking reagent in PBS-T over night at 4° C or 1 h at room temperature followed by anti-mouse IgG-POD (1:10000 in PBS-T) for 1 h at room temperature. That way, the 4G8 reprobing signals were essentially added on top of the initial signals and background artifacts.</p>
</sec>
<sec id="s4l">
<title>Capillary Isoelectric Focusing Immunoassay</title>
<p>Automated capillary isoelectric focusing immunoassays were performed with a Peggy-Sue system (ProteinSimple,San Jose, California, USA), essentially as previously described [<xref ref-type="bibr" rid="c96">96</xref>] and [<xref ref-type="bibr" rid="c53">53</xref>].</p>
<p>In brief, synthetic Aβ peptide variants were separated by isoelectric focusing in microcapillaries followed by photochemical immobilization to the inner capillary walls and probing with the primary antibodies for 120 min. After 2 washes, the horseradish peroxidase conjugated secondary antibodies were loaded and incubated for 60 min. After two washing steps, a luminol/peroxide mix was loaded, and chemiluminescent signals were recorded. The data was analyzed with the Compass for SW software. The following secondary antibodies were used: Anti-human IgG Secondary HRP antibody (Protein Simple, catalog number 043- 491), Goat-Anti-Mouse-HRP Secondary Antibody ProteinSimple, catalog number 040-655) and Peroxidase-conjugated Affini Pure Donkey Anti-Human IgG (H+L) (1:100 dilution) (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, code number 709-035-149).</p>
</sec>
<sec id="s4m">
<title>Automated Solid Phase Peptide Synthesis</title>
<p>The peptides were synthesized using PurePep Chorus (Gyros Protein Technologies, US) with Fmoc chemistry at 0.05mmol scale. Tentagel S RAM (Resin Substitution 0.22mmol/g - Rapp Polymere, Germany) resin was first swollen in dimethylformamide (DMF) for 30-60 minutes. Next, Fmoc was removed using a 20% piperidine in DMF solution for 1-2 minutes and washed 3x with DMF. Deprotection steps were performed at 90°C for unphosphorylated peptides and at room temperature from the first phospho-serine coupling. The peptide chain was elongated by adding the premixed amino acid (AA, 125mM and Oxyma 125mM) along with N,N’- diisopropylcarbodiimide (DIC, 250mM). The mixture was heated at 90°C for 2 minutes and then washed 2x with DMF. Capping was done with acetic anhydride (10% in DMF) for 5 minutes and washed 3x with DMF. The peptide chain was elongated until completion and dried for 30 minutes after 7x DCM washes. The Fmoc deprotected peptides were cleaved from the resin using a mixture of 90% TFA, 5% water, 3% TIPS, and 2% DCM for 4 h at RT. The peptides were then precipitated in ice-cold ether ON, subsequently purified using HPLC and analysed by LC-MS, as described below.</p>
</sec>
<sec id="s4n">
<title>Purification and Characterization of Peptides</title>
<p>The crude peptides were purified by reverse phase (RP) HPLC using a water-acetonitrile gradient with 0.1% formic acid (FA). Preparative HPLC was performed on a UltiMate™ 3000 HPLC Systems instrument (ThermoFisher Scientific, Waltham, Massachusetts, USA) equipped with RS variable wavelength detector (set to 215nm) and a Kinetex® 5µm EVO C18 100 LC column (00D-4633-P0-AX; Phenomenex, Aschaffenburg, Germany). Chromatograms were recorded using Chromeleon software v7.2. Purity and structural identity of the peptides were verified using a DAD equipped 1260 Infinity II HPLC device with a C18 RP column (Onyx Monolithic C18 50×2 mm), coupled to a mass selective detector with a single quadrupole system (Agilent Technologies, Santa Clara, CA, US) in ESI+ mode.</p>
<p>Crude phosphorylated pSer8-Aβ1-40 with an amidated C-terminal carboxyl group was purified on a 10x150mm Waters (Milford, Massachusetts, USA) XBridge Protein BEH C4 OBD preparative column (300Å, 5 µm) using 3% acetonitrile/0.2% Formic acid as solvent A and 97% acetonitrile/0.2% FA as solvent B. A Beckman System Gold HPLC system with external column oven was used to form the following gradient with a flow rate of 3.8 ml/min at 50°C column temperature: 5-20% B in 2 min, 20-32% B in 22 min, 32-50% in 5 min. Analytical HPLC was performed on a Waters Alliance e2695 HPLC system coupled to a photodiode array (PDA) optic detector and a single quadrupole QDa mass detector. A 4.6x150mm Waters XBridge Protein BEH C4 analytical column (300 Å, 3.5µm) was used at a flow rate of 3.8ml/min at 50°C column temperature; the corresponding gradient was 5-20% B in 2 min, 20- 32% B in 11 min, 32-50% in 5 min.</p>
</sec>
<sec id="s4o">
<title>Biolayer Interferometry</title>
<p>The samples were dispensed into a 96 microplate (Greiner bio-one GmbH, Frickenhausen, Germany) at a final volume of 200 μL. The binding of Aducanumab biosimilar and mAb 1E4E11 and their phosphorylated, unphosphorylated and H6R epitopes 6xHis-tagged were measured using Biolayer interferometry on an Octet RED 96system (Sartorius, Göttingen, Germany). The peptides were synthesized (purity above 98% - based on UV at 215nm) with Fmoc-Adoa linker (Iris - FAA1435) and C-terminal 6xHis tag. Sensorgrams were measured in double reference against the buffer and the reference sensor signals.</p>
<p>NTA biosensors (Sartorius, Göttingen, Germany) were preincubated into 1XPBS buffer pH 7.4, 0.2% BSA, 0.02% (v/v) Tween 20 for 10 min. A first baseline was established in the same buffer. The 6xHis peptides were loaded onto NTA biosensors at 20 μg/ml for 200 s. Following a buffer wash of 120s, the biosensors were incubated with serial-dilutions of the respective antibodies for 1200s s to measure association and then into buffer for additional 1500s to observe the dissociation phase. Experiments were performed at 30 °C and sample plates were shaken at 1000 rpm. Sensorgrams were globally fitted using Data Analysis software version 12.0.2.3 (Sartorius, Göttingen, Germany) with a 1:1 binding model.</p>
</sec>
<sec id="s4p">
<title>Immunoprecipitation and Mass Spectrometry</title>
<p>Antibodies were covalently coupled to Dynabeads M-270 Epoxy (Invitrogen/ThermoFisher Scientific, Waltham, Massachusetts, USA Cat. No. 14311 D), essentially following the manufacturer’s instructions. Tween-20 was omitted from all wash and storage buffers for specific use in IP-MS. In brief, 5 mg of M-270 epoxy beads were weighed into a 1.5-mL reaction vial and washed with 1 mL of buffer C1 (kit component). The bead suspension was divided in aliquots of 200 µL (containing 1mg of beads). The vials were placed on a magnetic stand for a few minutes, and the supernatant was carefully removed and discarded. Washed beads were resuspended in 40 µL of buffer C1 and 10 μL of antibody stock solution (1 mg/mL). After gentle mixing by pipetting, 50 μL of buffer C2 (kit component) was added and incubated overnight at 37 °C on a mixer. After coupling, the beads were washed one time with 400 μL of buffer HB (kit component), one time with 400 μL of buffer LB (kit component) and two times with 400 μL of PBS. After a final wash with PBS for 15 min with continuous agitation, the beads were resuspended in 100 µL PBS/0.1% BSA/0.02% NaN<sub>3</sub> and stored at 4 °C.</p>
<p>The synthetic Aβ peptides Aβ1–40, pSer8-Aβ1–40, Aβ1–42, Aβ2–40, Aβ3–40, AβpyGlu–40, Aβ4–40, Aβ5–40 and Aβ11–40 Aβ−3–40 (see above), were mixed and diluted to final concentrations of 10ng/mL of each in PBS/0.1%BSA containing phosphatase inhibitors (PhosphoStop Mini, Roche, Ref 04906837001) and protease inhibitors (Complete Mini Roche, Ref 04693124001). For immunoprecipitation of Aβ peptides, 250 µL of the Aβ mix or of pooled CSF was combined with an equal volume of 100 mM Tris-HCl, pH 7.4, containing 0.2% (w/v) nonyl-β-d-thiomaltoside (NTM) and 0.2% (w/v) n-dodecyl-β-d-maltoside (DDM) and 15 μL of functionalized M270 epoxy beads. After overnight incubation at 4 °C with constant mixing, the beads were washed five times with 0.5 mL of 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% (w/v) DDM, 0.1% (w/v) NTM and resuspended in 0.5 mL of 50 mM ammonium acetate (pH approximately 7.0). The beads were immediately forwarded to sample preparation for mass spectrometry. There, the beads were immobilised on a magnet, the supernatant was removed, and the beads were washed one time with 0.5 mL of 50 mM ammonium acetate, and one time with 0.5 mL H<sub>2</sub>O. The bound Aβ peptides were eluted in 2.5 μL of 70% acetonitrile containing 5 mM HCl.</p>
<p>Analysis by MALDI-TOF-MS was essentially performed as described [<xref ref-type="bibr" rid="c21">21</xref>,<xref ref-type="bibr" rid="c97">97</xref>]. Briefly, the eluates (0.5 µL) from synthetic samples were spotted onto a pre-structured MALDI sample support (MTP AnchorChip 384 BC; Cat. No. 8280790, Bruker, Bremen, Germany), followed by the addition of 0.5 µl TOPAC matrix solution, a matrix recently developed for the improved detection of intact phosphorylated Aβ peptides [<xref ref-type="bibr" rid="c82">82</xref>]. Alternatively, conventional CHCA matrix was used for CSF samples as described in [<xref ref-type="bibr" rid="c21">21</xref>]. A 1:1 mixture of Peptide Calibration Standard II (Cat. No. 8222570, Bruker, Bremen, Germany) and PepMix2 (Cat. No. C102, LaserBio Labs, Valbonne, France) was used as calibrant. The samples were dried in a vacuum desiccator and a total of 5000 mass spectra per spot were recorded using an ultrafleXtreme MALDI- TOF/TOF mass spectrometer in reflector mode operated under the software flexControl 3.4 (Bruker, Bremen, Germany).</p>
</sec>
<sec id="s4q">
<title>Immunohistochemistry and Antibody Preadsorption</title>
<p>Immunohistochemistry was performed on 4-μm paraffin sections. In brief, brain sections were deparaffinized in Roticlear (Carl Roth, Karlsruhe, Germany) and rehydrated in a descending series of ethanol. Activity of endogenous peroxidases was blocked by incubation in 0.3% H<sub>2</sub>O<sub>2</sub> in PBS for 30 min. Antigen retrieval was achieved by initial boiling of the sections in 0.01 M citrate buffer (pH 6.0) and subsequent incubation in 88% formic acid for 3 min. Unspecific binding sites were blocked by incubation in PBS containing 4% skim milk and 10% fetal calf serum (FCS) for 1 h at room temperature, prior to the overnight incubation with the primary antibodies. The following antibodies were used for the detection of different Aβ variants: Aducanumab<sub>bs</sub> (0.5 µg/µl), Donanemab<sub>bs</sub> (1 µg/ml), Lecanemab<sub>bs</sub> (0.06 µg/ml).</p>
<p>Antibody pre-adsorption with synthetic Aβ peptides (Aβ1-16 ( synthesized at Neuroproteomics Group, Max-Planck Institute for Multidisciplary Sciences (MPI-NAT), Göttingen), Aβ1-34, Aβ1-38, Aβ1-40, Aβ3-40 (from Anaspec), AβpE-40 (Peptide Speciality Laboratory, Heidelberg, Germany), Aβ1-42 monomers, Aβ1-42 oligomers and Aβ1-42 fibrils (StressMarq, Victoria, Canada) was carried out as described previously [<xref ref-type="bibr" rid="c52">52</xref>]. In brief, 1 µg Donanemab<sub>bs</sub> was blocked with 2.5 µg of Aβ1-40, Aβ3-40 or AβpE3-40 in 0.01 M PBS including 10% FCS. In the case of Aducanumab<sub>bs</sub>, 0.5 µg of the antibody were blocked with 10 µg of Aβ1-42 monomers or 5 µg of Aβ1-42 fibrils. For Lecanemab<sub>bs</sub>, 0.06 µg of antibody (PX-TA1746) was blocked with 0.25 µg of Aβ1-42 monomers, oligomers or fibrils, or 0.06 µg (BXC-SIM0032) was blocked with 0.25 µg Aβ1-16, Aβ1-34, Aβ1-38 or Aβ1-42 monomers). Antibodies and peptides were incubated on a rotator for 3 h at room temperature and reaction tubes were centrifuged at 13000 rpm for 5 min at the end of the incubation period. Control conditions included antibodies in 0.01 M PBS including 10% FCS without synthetic peptides. Adjacent paraffin-embedded sections from a human AD case were incubated overnight with the supernatants and sections were washed with 0.01 M PBS including 0.1 % Tergitol. For detection, biotinylated anti-human antibodies (2.4 µg/ml, Jackson ImmunoResearch, West Grove, Pennsylvania, USA #109-065-003) were used and staining was visualized with the ABC method with a Vectastain kit (Vector Laboratories, Newark, California, USA), diaminobenzidine as a chromogen and counterstaining with hematoxylin.</p>
</sec>
</sec>
</body>
<back>
<sec sec-type="supplementary" id="supplementary34">
<fig id="fig1s1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1 - figure supplement 1.</label>
<caption><title>Titration series of N-terminal specific Anti-Aβs.</title>
<p>(a) Titration of monoclonal Aβ-Ab 3D6, 82E1 and 7H3D6 at concentrations ranging from 2 to 0.00041 µg/mL to study the selectivity for free-Asp(1) over Asp(1) within an N-terminal elongated peptide. The signals were normalized internally and presented as a heat map with blue-to-red shades ranging from 0 to 1. (b) Monoclonal Aβ-Ab 11H3D6 and 80C2 exhibited high selectivity towards free-Asp(1) across the chosen concentration range of 2 µg/mL down to 0.0041 µg/mL.</p></caption>
<graphic xlink:href="640323v2_fig1s1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="fig2s1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2 - figure supplement 1.</label>
<caption><title>N-terminally elongated Deep Mutational Scans of Aducanumab<sub>bs</sub> and 6E10 with core motifs summary.</title>
<p>(a) Fingerprint analysis for the first peptide group covering the sequence <italic>KTEEISEVKMDAEFRHDS</italic>. The Aβ-Ab tested here is Aducanumab<sub>bs.</sub> (b) Fingerprint analysis for the second peptide group covering the sequence <italic>VKMDAEFRHDSGYEVHHQ</italic>. The Aβ-Ab tested here is Aducanumab<sub>bs.</sub> (c) Fingerprint analysis of 6E10 on the sequence <italic>KTEEISEVKMDAEFRHDS</italic>. (d) Summary of the antibody core motifs, “X” within the sequence stands for non-conserved residue. When an amino acid variation led to a decrease in binding below 50% of wt, it was marked as dominant negative. If more than 10 amino acid substitutions were dominant negative, the entire position was designated as part of the core motif (represented in single-letter coding). (e) Aβ-Ab species preferences. Amino acid positions which are different in human and rat/mouse are highlighted in red. These specific positions were probed. Antibodies showing altered binding strength after replacing R5 or Y10 in the human Aβ sequence by G5 or F10 (rat/mouse Aβ sequence) are highlighted in blue. Human: Homo Sapiens; Dog: Canis Lupus Familiaris; Pig: Sus Scrofa; Rabbit: Oryctolagus Cuniculus; Sheep: Ovis Aries; Rat: Rattus Norvegicus; Mouse: Mus Musculus.</p></caption>
<graphic xlink:href="640323v2_fig2s1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="fig2s2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2 – figure supplement 2.</label>
<caption><title>Aβ1-15 carrying the English mutation (H6R) shows reduced affinity for Aducanumab<sub>bs.</sub></title><p><bold>(</bold>a) Dot Blot from the purified 6xHis peptides <italic>DAEFR<bold>H</bold>DSGYEVHHQ</italic> and <italic>DAEFR<bold>R</bold>DSGYEVHHQ</italic> were printed using Slide Spotter robot. IgG signals were detected using Goat anti-human DL650, in square brackets the µg/mL of Aducanumab<sub>bs.</sub> (b) The Biolayer interferometry responses of Aducanumab<sub>bs</sub> (10nM) over the NTA-loaded <italic>DAEFR<bold>H</bold>DSGYEVHHQ</italic> and <italic>DAEFR<bold>R</bold>DSGYEVHHQ</italic> peptides are shown.</p></caption>
<graphic xlink:href="640323v2_fig2s2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="fig3s1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3 – figure supplement 1.</label>
<caption><title>Antibody 1E4E11 shows high preference for phosphorylated pSer8 Aβ1-15 in µSPOT and BLI assays.</title>
<p>(a) Titration of monoclonal Aβ-Ab 1E4E11 at concentrations ranging from 0.25 to 0.001 µg/mL to achieve high selectivity for Aβ1-15 phosphorylated at Ser(8). The modified pSer is represented as ’2’. The signals were globally normalized against <italic>DAEFRHDpSGYEVHHQ</italic> and presented as a heat map with blue-to-red shades ranging from 0 to 1. (b) BLI dose-response curve of mAb 1E4E11 binding to the NTA-loaded <italic>DAEFRHDSGYEVHHQ-6xHis-amide</italic> peptide. (c) Biolayer interferometry dose-response curve of mAb 1E4E11 binding to the NTA-loaded <italic>DAEFRHDpSGYEVHHQ-6xHis-amide</italic> peptide. (d) BLI steady-state analysis revealed K<sub>D</sub>s of 4.1nM and 1.3µM for Aβ1-15 with phosphorylated and unphosphorylated Ser (8), respectively (1:1 model).</p></caption>
<graphic xlink:href="640323v2_fig3s1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="fig3s2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3 – figure supplement 2.</label>
<caption><title>Phosphorylation aids Aducanumab<sub>bs</sub> binding to synthetic monomeric Aβ1-15.</title><p>(a) Titration of Aducanumab<sub>bs</sub> at different concentrations to achieve high selectivity for phosphorylated pSer8-Aβ1-15 over unphosphorylated Aβ1-15. The signals were internally normalized and fitted as a sigmoidal curve (Boltzmann). The phospho signal for pSer8-Aβ1-15 is shown in red (r^2 0.98) and the signal for unphosphorylated Aβ1-15 is shown in blue (r^2 0.96). (b) BLI steady-state analysis revealed KDs of 1.4nM and 8.7nM for phosphorylated and unphosphorylated Aβ1-15, respectively (1:1 model). (c) Biolayer interferometry dose-response curve of Aducanumab binding to the NTA-loaded <italic>DAEFRHDSGYEVHHQ-6xHis-amide</italic> peptide. (d) Biolayer interferometry dose-response curve of Aducanumab binding to the NTA-loaded <italic>DAEFRHDpSGYEVHHQ-6xHis-amide</italic> peptide.</p></caption>
<graphic xlink:href="640323v2_fig3s2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="fig3s3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3 – figure supplement 3.</label>
<caption><title>MD simulation of Aducanumab with pSer(8)-Aβ2-8.</title>
<p>(a) Sticks and cartoon depiction of the MD simulations between Aducanumab and AEFRHDS. (b) Electrostatic density for the non-phosphorylated sequence interaction. (c-d) RMSD analysis of the backbone atoms of the unphosphorylated candidate (average conformation over 600ns). (e) Sticks and cartoon depiction of the MD simulations between Aducanumab and AEFRHDpS. (f) Electrostatic density for the pSer8 sequence interaction. (g-h) RMSD analysis of the backbone atoms of the PTM candidate (average conformation over 600ns).</p></caption>
<graphic xlink:href="640323v2_fig3s3.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="fig3s4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3 – figure supplement 4.</label>
<caption><title>pSer8 but not Ser8-Aβ recapitulate the binding mode resolved by christallography.</title>
<p>Comparison of MD simulations with structural data. The MD simulation was conducted with the resolved epitope peptide <italic>EFRHDS,</italic> but in the absence of additional ions, and predicts a largely altered binding mode characterized by over 10 Å movements of R317 and R318. In contrast, the crystal structure (PDB 6CO3) harbors a sulfate ion that neutralizes the positive charge introduced by R317 and R318. Strikingly the MD of the pSer(8) modified peptide recapitulates the resolved X-ray binding mode to monomeric Aβ. Aducanumab targets aggregated Aβ, while still engaging with low micromolar affinity a monomeric Aβ.</p></caption>
<graphic xlink:href="640323v2_fig3s4.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="fig6s1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6 – figure supplement 1.</label>
<caption><title>HFIP treated Aβ1-42, but not shorter synthetic Aβ-peptides block Lecanemab<sub>bs</sub> binding to amyloid plaques.</title>
<p>Parallel sections from an AD patient were stained, from left to write, with Lecanemab<sub>bs</sub> only (BioXCell #BXC-SIM0032) or pre-adsorbed with either Aβ1-42 monomers (Aβ1-42m), Aβ1-16 (Aβ1-16), Aβ1-34 (Aβ1-34) and Aβ1-38 (Aβ1-38). Scale bar: 200 µm.</p></caption>
<graphic xlink:href="640323v2_fig6s1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<ack>
<title>Acknowledgements</title>
<p>First, we thank Sonja Kachler, Gabriele Paetzold and Sandra Theil for the excellent technical assistance. Also, we would like to thank Prof. S. Weggen (Heinrich Heine University, Germany) to have kindly provided the IC16 Antibody. We thank Prof. H.-J. Knölker (Technische Universität Dresden, Germany) for providing the synthetic Aβ-3-40 peptide. We thank Niels Hansen and Anke Jahn Brodmann for support and for providing CSF-samples from the local biobank. H.M.M. acknowledge funding by the Interdisziplinäres Zentrum für Klinische Forschung (IZKF) of Würzburg, project number A-F-N-419. H.M.M. acknowledges the Junior Group Leader program of the Rudolf Virchow Center, the excellent ideas programme of the University of Würzburg and support through the Emmy Noether Programme of the Deutsche Forschungsgemeinschaft (DFG) (MA6957/1-1). T.L. acknowledges funding by the Graduate School of Life Sciences of the University of Würzburg. O.W. acknowledges funding by the DFG (WI3472/11-1 and Research Training Group 2824 (RTG2824)). J.W acknowledges funding by the DFG WA1477/6-6. M.M.H is a member of RTG 2824 funded by the DFG. M.M.H. is supported as a doctoral student of the GRK 2824 – Project number 465640801 funded by the DFG.</p>
</ack>
<sec id="additional-info" sec-type="additional-information">
<title>Additional information</title>
<sec id="s5">
<title>Author contributions</title>
<p>The following section was based on the CRediT system. Conceptualization: IT, HMM; Methodology: IT, HMM, HWK, OJ, OW; Formal Analysis: IT, HMM, TLe, HWK, OJ, OW, SB, LvW, TLi; Investigation: IT, TLe, HWK, MMH, SA, BM, SB, LvW, TLi; Visualization: IT, TLe; Writing – Original Draft: HMM, IT; Writing – review &amp; editing: all the co-authors; Project administration: IT, HMM; Supervision: HMM, HWK, OJ, OW, JW, HS, JoW, JeW; Funding Acquisition, HMM.</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Colvin</surname>, <given-names>M.T.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Atomic Resolution Structure of Monomorphic Aβ42 Amyloid Fibrils</article-title>. <source>Journal of the American Chemical Society</source> <volume>138</volume>, <fpage>9663</fpage>–<lpage>9674</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.6b05129</pub-id></mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>, <given-names>Y.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2022</year>) <article-title>Cryo-EM structures of amyloid-β 42 filaments from human brains</article-title>. <source>Science</source> <volume>375</volume>, <fpage>167</fpage>–<lpage>172</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.abm7285</pub-id></mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tzioras</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2023</year>) <article-title>Synaptic degeneration in Alzheimer disease</article-title>. <source>Nature Reviews Neurology</source> <volume>19</volume>, <fpage>19</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1038/s41582-022-00749-z</pub-id></mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kent</surname>, <given-names>S.A.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020</year>) <article-title>The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics</article-title>. <source>Acta Neuropathologica</source> <volume>140</volume>, <fpage>417</fpage>–<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-020-02196-w</pub-id></mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vassar</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal></person-group> (<year>1999</year>) <article-title>β-Secretase Cleavage of Alzheimer’s Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE</article-title>. <source>Science</source> <volume>286</volume>, <fpage>735</fpage>–<lpage>741</lpage>. <pub-id pub-id-type="doi">10.1126/science.286.5440.735</pub-id></mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wolfe</surname>, <given-names>M.S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>1999</year>) <article-title>Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity</article-title>. <source>Nature</source> <volume>398</volume>, <fpage>513</fpage>–<lpage>517</lpage>. <pub-id pub-id-type="doi">10.1038/19077</pub-id></mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wiltfang</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2002</year>) <article-title>Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer’s disease and in patients with chronic neuroinflammation</article-title>. <source>Journal of Neurochemistry</source> <volume>81</volume>, <fpage>481</fpage>–<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.00818.x</pub-id></mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mukherjee</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>) <article-title>Citrullination of Amyloid-β Peptides in Alzheimer’s Disease</article-title>. <source>ACS Chemical Neuroscience</source> <volume>12</volume>, <fpage>3719</fpage>–<lpage>3732</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.1c00474</pub-id></mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scheidt</surname>, <given-names>H.A.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020</year>) <article-title>Structural characteristics of oligomers formed by pyroglutamate-modified amyloid β peptides studied by solid-state NMR</article-title>. <source>Physical Chemistry Chemical Physics</source> <volume>22</volume>, <fpage>16887</fpage>–<lpage>16895</lpage>. <pub-id pub-id-type="doi">10.1039/D0CP02307H</pub-id></mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grochowska</surname>, <given-names>K.M.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction</article-title>. <source>EMBO reports</source> <volume>18</volume>, <fpage>962</fpage>–<lpage>981</lpage>. <pub-id pub-id-type="doi">10.15252/embr.201643519</pub-id></mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roher</surname>, <given-names>A.E.</given-names></string-name> <etal>et al.</etal></person-group> (<year>1993</year>) <article-title>Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer’s disease</article-title>. <source>Journal of Biological Chemistry</source> <volume>268</volume>, <fpage>3072</fpage>–<lpage>3083</lpage>. <pub-id pub-id-type="doi">10.1016/S0021-9258(18)53661-9</pub-id></mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moro</surname>, <given-names>M.L.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease</article-title>. <source>Acta Neuropathologica Communications</source> <volume>6</volume>, <issue>3</issue>. <pub-id pub-id-type="doi">10.1186/s40478-017-0505-x</pub-id></mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schrempel</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>Identification of isoAsp7-Aβ as a major Aβ variant in Alzheimer’s disease, dementia with Lewy bodies and vascular dementia</article-title>. <source>Acta Neuropathologica</source> <volume>148</volume>, <issue>78</issue>. <pub-id pub-id-type="doi">10.1007/s00401-024-02824-9</pub-id></mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>) <article-title>Novel Phosphorylation-State Specific Antibodies Reveal Differential Deposition of Ser26 Phosphorylated Aβ Species in a Mouse Model of Alzheimer’s Disease</article-title>. <source>Frontiers in Molecular Neuroscience</source> <volume>13</volume>. <pub-id pub-id-type="doi">10.3389/fnmol.2020.619639</pub-id></mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ashby</surname>, <given-names>E.L.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2015</year>) <article-title>Investigation of Aβ phosphorylated at serine 8 (pAβ) in Alzheimer’s disease, dementia with Lewy bodies and vascular dementia</article-title>. <source>Neuropathology and Applied Neurobiology</source> <volume>41</volume>, <fpage>428</fpage>–<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1111/nan.12212</pub-id></mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2012</year>) <article-title>Phosphorylation of Amyloid-β Peptide at Serine 8 Attenuates Its Clearance via Insulin-degrading and Angiotensin-converting Enzymes*</article-title>. <source>Journal of Biological Chemistry</source> <volume>287</volume>, <fpage>8641</fpage>–<lpage>8651</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.279133</pub-id></mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wirths</surname>, <given-names>O.</given-names></string-name> and <string-name><surname>Zampar</surname>, <given-names>S</given-names></string-name></person-group>. (<year>2019</year>) <article-title>Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease</article-title>. <source>Expert Opinion on Therapeutic Targets</source> <volume>23</volume>, <fpage>991</fpage>–<lpage>1004</lpage>. <pub-id pub-id-type="doi">10.1080/14728222.2019.1702972</pub-id></mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shinohara</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-β42 in Alzheimer’s disease</article-title>. <source>Brain</source> <volume>140</volume>, <fpage>3301</fpage>–<lpage>3316</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awx284</pub-id></mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reinert</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models</article-title>. <source>Acta Neuropathologica Communications</source> <volume>4</volume>, <issue>24</issue>. <pub-id pub-id-type="doi">10.1186/s40478-016-0294-7</pub-id></mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moro</surname>, <given-names>M.L.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2012</year>) <article-title>APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38</article-title>. <source>Acta Neuropathologica</source> <volume>124</volume>, <fpage>809</fpage>–<lpage>821</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-012-1061-x</pub-id></mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wirths</surname>, <given-names>O.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>Amino-terminally elongated Aβ peptides are generated by the secreted metalloprotease ADAMTS4 and deposit in a subset of Alzheimer’s disease brains</article-title>. <source>Neuropathology and Applied Neurobiology</source> <volume>50</volume>, <fpage>e12991</fpage>. <pub-id pub-id-type="doi">10.1111/nan.12991</pub-id></mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sinha</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>1999</year>) <article-title>Purification and cloning of amyloid precursor protein β-secretase from human brain</article-title>. <source>Nature</source> <volume>402</volume>, <fpage>537</fpage>–<lpage>540</lpage>. <pub-id pub-id-type="doi">10.1038/990114</pub-id></mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Walter</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2019</year>) <article-title>The metalloprotease ADAMTS4 generates N-truncated Aβ4–x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer’s disease</article-title>. <source>Acta Neuropathologica</source> <volume>137</volume>, <fpage>239</fpage>–<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-018-1929-5</pub-id></mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wirths</surname>, <given-names>O.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>) <article-title>N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models</article-title>. <source>Alzheimer’s Research &amp; Therapy</source> <volume>9</volume>, <issue>80</issue>. <pub-id pub-id-type="doi">10.1186/s13195-017-0309-z</pub-id></mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seuma</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>) <article-title>The genetic landscape for amyloid beta fibril nucleation accurately discriminates familial Alzheimer’s disease mutations</article-title>. <source>eLife</source> <volume>10</volume>, <elocation-id>e63364</elocation-id>. <pub-id pub-id-type="doi">10.7554/eLife.63364</pub-id></mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paravastu</surname>, <given-names>A.K.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2008</year>) <article-title>Molecular structural basis for polymorphism in Alzheimer’s amyloid fibrils</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>105</volume>, <fpage>18349</fpage>–<lpage>18354</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0806270105</pub-id></mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tycko</surname>, <given-names>R</given-names></string-name></person-group>. (<year>2015</year>) <article-title>Amyloid Polymorphism: Structural Basis and Neurobiological Relevance</article-title>. <source>Neuron</source> <volume>86</volume>, <fpage>632</fpage>–<lpage>645</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.03.017</pub-id></mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qiang</surname>, <given-names>W.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Structural variation in amyloid-β fibrils from Alzheimer’s disease clinical subtypes</article-title>. <source>Nature</source> <volume>541</volume>, <fpage>217</fpage>–<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1038/nature20814</pub-id></mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname>, <given-names>J.-X.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Molecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue</article-title>. <source>Cell</source> <volume>154</volume>, <fpage>1257</fpage>–<lpage>1268</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.08.035</pub-id></mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rasmussen</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer’s disease</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>114</volume>, <fpage>13018</fpage>–<lpage>13023</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1713215114</pub-id></mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barykin</surname>, <given-names>E.P.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Amyloid β Modification: A Key to the Sporadic Alzheimer’s Disease?</article-title> <source>Frontiers in Genetics</source> <volume>8</volume>. <pub-id pub-id-type="doi">10.3389/fgene.2017.00058</pub-id></mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kummer</surname>, <given-names>M.P.</given-names></string-name> and <string-name><surname>Heneka</surname>, <given-names>M.T</given-names></string-name></person-group>. (<year>2014</year>) <article-title>Truncated and modified amyloid-beta species</article-title>. <source>Alzheimer’s Research &amp; Therapy</source> <volume>6</volume>, <issue>28</issue>. <pub-id pub-id-type="doi">10.1186/alzrt258</pub-id></mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roher</surname>, <given-names>A.E.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>) <article-title>APP/Aβ structural diversity and Alzheimer’s disease pathogenesis</article-title>. <source>Neurochemistry International</source> <volume>110</volume>, <fpage>1</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2017.08.007</pub-id></mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gómez-Castro</surname>, <given-names>C.Z.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>An N-terminal acidic β-sheet domain is responsible for the metal-accumulation properties of amyloid-β protofibrils: a molecular dynamics study</article-title>. <source>JBIC Journal of Biological Inorganic Chemistry</source> <pub-id pub-id-type="doi">10.1007/s00775-024-02061-1</pub-id></mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gessel</surname>, <given-names>M.M.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2012</year>) <article-title>Familial Alzheimer’s Disease Mutations Differentially Alter Amyloid β-Protein Oligomerization</article-title>. <source>ACS Chemical Neuroscience</source> <volume>3</volume>, <fpage>909</fpage>–<lpage>918</lpage>. <pub-id pub-id-type="doi">10.1021/cn300050d</pub-id></mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hatami</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Familial Alzheimer’s Disease Mutations within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-β Peptide* *This work was supported by National Institutes of Health Grants AG033069 and AG00538 and a grant from the Cure Alzheimer’s fund. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health</article-title>. <source>Journal of Biological Chemistry</source> <volume>292</volume>, <fpage>3172</fpage>–<lpage>3185</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.755264</pub-id></mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jang</surname>, <given-names>H.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Familial Alzheimer’s Disease Osaka Mutant (ΔE22) β-Barrels Suggest an Explanation for the Different Aβ1–40/42 Preferred Conformational States Observed by Experiment</article-title>. <source>The Journal of Physical Chemistry B</source> <volume>117</volume>, <fpage>11518</fpage>–<lpage>11529</lpage>. <pub-id pub-id-type="doi">10.1021/jp405389n</pub-id></mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Söderberg</surname>, <given-names>L.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities</article-title>. <source>Scientific Reports</source> <volume>14</volume>, <fpage>10868</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-024-61691-2</pub-id></mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Dyck</surname>, <given-names>C.H.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise</article-title>. <source>Biological Psychiatry</source> <volume>83</volume>, <fpage>311</fpage>–<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2017.08.010</pub-id></mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sevigny</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2016</year>) <article-title>The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease</article-title>. <source>Nature</source> <volume>537</volume>, <fpage>50</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1038/nature19323</pub-id></mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arndt</surname>, <given-names>J.W.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β</article-title>. <source>Scientific Reports</source> <volume>8</volume>, <fpage>6412</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-24501-0</pub-id></mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feinberg</surname>, <given-names>H.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab</article-title>. <source>Alzheimer’s Research &amp; Therapy</source> <volume>6</volume>, <issue>31</issue>. <pub-id pub-id-type="doi">10.1186/alzrt261</pub-id></mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Budd Haeberlein</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2022</year>) <article-title>Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease</article-title>. <source>J Prev Alzheimers Dis</source> <volume>9</volume>, <fpage>197</fpage>–<lpage>210</lpage>. <pub-id pub-id-type="doi">10.14283/jpad.2022.30</pub-id></mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dyer</surname>, <given-names>O</given-names></string-name></person-group>. (<year>2024</year>) <article-title>Aduhelm: Biogen abandons Alzheimer’s drug after controversial approval left it unfunded by Medicare</article-title>. <source>BMJ</source> <volume>384</volume>, <issue>q281</issue>. <pub-id pub-id-type="doi">10.1136/bmj.q281</pub-id></mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Honig</surname>, <given-names>L.S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease</article-title>. <source>Alzheimers Res Ther</source> <volume>16</volume>, <issue>105</issue>. <pub-id pub-id-type="doi">10.1186/s13195-024-01441-8</pub-id></mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peralta Reyes</surname>, <given-names>F.S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2025</year>) <article-title>Lecanemab Binds to Transgenic Mouse Model- Derived Amyloid-beta Fibril Structures Resembling Alzheimer’s Disease Type I, Type II and Arctic Folds</article-title>. <source>Neuropathol Appl Neurobiol</source> <volume>51</volume>, <fpage>e70022</fpage>. <pub-id pub-id-type="doi">10.1111/nan.70022</pub-id></mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sims</surname>, <given-names>J.R.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2023</year>) <article-title>Donanemab in Early Symptomatic Alzheimer Disease</article-title>. <source>JAMA</source> <volume>330</volume>, <fpage>512</fpage>–<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2023.13239</pub-id></mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dyck</surname>, <given-names>C.H.v.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2023</year>) <article-title>Lecanemab in Early Alzheimer’s Disease</article-title>. <source>New England Journal of Medicine</source> <volume>388</volume>, <fpage>9</fpage>–<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2212948</pub-id></mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mintun</surname>, <given-names>M.A.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>) <article-title>Donanemab in Early Alzheimer’s Disease</article-title>. <source>New England Journal of Medicine</source> <volume>384</volume>, <fpage>1691</fpage>–<lpage>1704</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2100708</pub-id></mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shcherbinin</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2022</year>) <article-title>Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial</article-title>. <source>JAMA Neurology</source> <volume>79</volume>, <fpage>1015</fpage>–<lpage>1024</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2022.2793</pub-id></mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Britschgi</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2009</year>) <article-title>Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>106</volume>, <fpage>12145</fpage>–<lpage>12150</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0904866106</pub-id></mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klafki</surname>, <given-names>H.-W.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2022</year>) <article-title>Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?</article-title> <source>Fluids and Barriers of the CNS</source> <volume>19</volume>, <issue>96</issue>. <pub-id pub-id-type="doi">10.1186/s12987-022-00390-4</pub-id></mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zampar</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020</year>) <article-title>N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer’s disease</article-title>. <source>Neuropathology and Applied Neurobiology</source> <volume>46</volume>, <fpage>673</fpage>–<lpage>685</lpage>. <pub-id pub-id-type="doi">10.1111/nan.12637</pub-id></mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Savastano</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2016</year>) <article-title>N-Truncated Aβ 2-X Starting with Position Two in Sporadic Alzheimer’s Disease Cases and Two Alzheimer Mouse Models</article-title>. <source>Journal of Alzheimer’s Disease</source> <volume>49</volume>, <fpage>101</fpage>–<lpage>110</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-150394</pub-id></mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baghallab</surname>, <given-names>I.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Epitomic Characterization of the Specificity of the Anti- Amyloid Aβ Monoclonal Antibodies 6E10 and 4G8</article-title>. <source>Journal of Alzheimer’s Disease</source> <volume>66</volume>, <fpage>1235</fpage>–<lpage>1244</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-180582</pub-id></mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bader</surname>, <given-names>A.S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2023</year>) <article-title>Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice</article-title>. <source>Life</source> <volume>13</volume>, <fpage>1053</fpage></mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer’s disease</article-title>. <source>Acta Neuropathologica</source> <volume>125</volume>, <fpage>699</fpage>–<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-013-1107-8</pub-id></mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nussbaum</surname>, <given-names>J.M.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2012</year>) <article-title>Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β</article-title>. <source>Nature</source> <volume>485</volume>, <fpage>651</fpage>–<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1038/nature11060</pub-id></mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bayer</surname>, <given-names>T.A.</given-names></string-name> and <string-name><surname>Wirths</surname>, <given-names>O</given-names></string-name></person-group>. (<year>2014</year>) <article-title>Focusing the amyloid cascade hypothesis on N- truncated Abeta peptides as drug targets against Alzheimer’s disease</article-title>. <source>Acta Neuropathologica</source> <volume>127</volume>, <fpage>787</fpage>–<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-014-1287-x</pub-id></mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klafki</surname>, <given-names>H.W.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020</year>) <article-title>Development and Technical Validation of an Immunoassay for the Detection of APP669–711 (Aβ−3–40) in Biological Samples</article-title>. <source>International Journal of Molecular Sciences</source> <volume>21</volume>, <fpage>6564</fpage></mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Richter</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2010</year>) <article-title>Amyloid beta 42 peptide (Aβ42)-lowering compounds directly bind to Aβ and interfere with amyloid precursor protein (APP) transmembrane dimerization</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>107</volume>, <fpage>14597</fpage>–<lpage>14602</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1003026107</pub-id></mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dornieden</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Characterization of a Single-Chain Variable Fragment Recognizing a Linear Epitope of Aβ: A Biotechnical Tool for Studies on Alzheimer’s Disease?</article-title> <source>PLOS One</source> <volume>8</volume>, <fpage>e59820</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0059820</pub-id></mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jäger</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2009</year>) <article-title>α-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Aβ generation</article-title>. <source>Journal of Neurochemistry</source> <volume>111</volume>, <fpage>1369</fpage>–<lpage>1382</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06420.x</pub-id></mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DeMattos</surname>, <given-names>Ronald B.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2012</year>) <article-title>A Plaque-Specific Antibody Clears Existing β- amyloid Plaques in Alzheimer’s Disease Mice</article-title>. <source>Neuron</source> <volume>76</volume>, <fpage>908</fpage>–<lpage>920</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.10.029</pub-id></mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaneko</surname>, <given-names>N.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Novel plasma biomarker surrogating cerebral amyloid deposition. <italic>Proceedings of the Japan Academy</italic></article-title>, <source>Series B</source> <volume>90</volume>, <fpage>353</fpage>–<lpage>364</lpage>. <pub-id pub-id-type="doi">10.2183/pjab.90.353</pub-id></mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nakamura</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2018</year>) <article-title>High performance plasma amyloid-β biomarkers for Alzheimer’s disease</article-title>. <source>Nature</source> <volume>554</volume>, <fpage>249</fpage>–<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1038/nature25456</pub-id></mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Van Cauwenberghe</surname>, <given-names>C.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>) <article-title>The genetic landscape of Alzheimer disease: clinical implications and perspectives</article-title>. <source>Genetics in Medicine</source> <volume>18</volume>, <fpage>421</fpage>–<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2015.117</pub-id></mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weggen</surname>, <given-names>S.</given-names></string-name> and <string-name><surname>Beher</surname>, <given-names>D</given-names></string-name></person-group>. (<year>2012</year>) <article-title>Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer’s disease</article-title>. <source>Alzheimer’s Research &amp; Therapy</source> <volume>4</volume>, <issue>9</issue>. <pub-id pub-id-type="doi">10.1186/alzrt107</pub-id></mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>, <given-names>W.T.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2012</year>) <article-title>Amyloid-beta (Aβ) D7H mutation increases oligomeric Aβ42 and alters properties of Aβ-zinc/copper assemblies</article-title>. <source>PLoS One</source> <volume>7</volume>, <fpage>e35807</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0035807</pub-id></mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wakutani</surname>, <given-names>Y.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2004</year>) <article-title>Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer’s disease. <italic>Journal of Neurology</italic></article-title>, <source>Neurosurgery &amp; Psychiatry</source> <volume>75</volume>, <issue>1039</issue>. <pub-id pub-id-type="doi">10.1136/jnnp.2003.010611</pub-id></mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Janssen</surname>, <given-names>J.C.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2003</year>) <article-title>Early onset familial Alzheimer’s disease</article-title>. <source>Neurology</source> <volume>60</volume>, <fpage>235</fpage>–<lpage>239</lpage>. doi:<pub-id pub-id-type="doi">10.1212/01.WNL.0000042088.22694.E3</pub-id></mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jones</surname>, <given-names>C.T.</given-names></string-name> <etal>et al.</etal></person-group> (<year>1992</year>) <article-title>Mutation in codon 713 of the β amyloid precursor protein gene presenting with schizophrenia</article-title>. <source>Nature Genetics</source> <volume>1</volume>, <fpage>306</fpage>–<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1038/ng0792-306</pub-id></mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peacock</surname>, <given-names>M.L.</given-names></string-name> <etal>et al.</etal></person-group> (<year>1993</year>) <article-title>Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer’s disease</article-title>. <source>Neurology</source> <volume>43</volume>, <fpage>1254</fpage>–<lpage>1254</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.43.6.1254</pub-id></mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jonsson</surname>, <given-names>T.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2012</year>) <article-title>A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline</article-title>. <source>Nature</source> <volume>488</volume>, <fpage>96</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1038/nature11283</pub-id></mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yi</surname>, <given-names>Y.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020</year>) <article-title>An APP mutation family exhibiting white matter hyperintensities and cortical calcification in East China</article-title>. <source>Neurological Sciences</source> <volume>41</volume>, <fpage>2921</fpage>–<lpage>2928</lpage>. <pub-id pub-id-type="doi">10.1007/s10072-020-04342-4</pub-id></mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jiang</surname>, <given-names>B.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Mutation screening in Chinese patients with familial Alzheimer’s disease by whole-exome sequencing</article-title>. <source>Neurobiology of Aging</source> <volume>76</volume>, <issue>215</issue>.<fpage>e215</fpage>–<lpage>215.e221.</lpage> <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.11.024</pub-id></mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Obici</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2005</year>) <article-title>A novel AβPP mutation exclusively associated with cerebral amyloid angiopathy</article-title>. <source>Annals of Neurology</source> <volume>58</volume>, <fpage>639</fpage>–<lpage>644</lpage>. <pub-id pub-id-type="doi">10.1002/ana.20571</pub-id></mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aggarwal</surname>, <given-names>L.</given-names></string-name> and <string-name><surname>Biswas</surname>, <given-names>P</given-names></string-name></person-group>. (<year>2021</year>) <article-title>Hydration Thermodynamics of the N-Terminal FAD Mutants of Amyloid-β</article-title>. <source>Journal of Chemical Information and Modeling</source> <volume>61</volume>, <fpage>298</fpage>–<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c01286</pub-id></mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Murakami</surname>, <given-names>K.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2003</year>) <article-title>Neurotoxicity and Physicochemical Properties of Aβ Mutant Peptides from Cerebral Amyloid Angiopathy</article-title>. <source>Journal of Biological Chemistry</source> <volume>278</volume>, <fpage>46179</fpage>–<lpage>46187</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M301874200</pub-id></mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schlenzig</surname>, <given-names>D.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2009</year>) <article-title>Pyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides</article-title>. <source>Biochemistry</source> <volume>48</volume>, <fpage>7072</fpage>–<lpage>7078</lpage>. <pub-id pub-id-type="doi">10.1021/bi900818a</pub-id></mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2011</year>) <article-title>Extracellular phosphorylation of the amyloid peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer’s disease</article-title>. <source>The EMBO Journal</source> <volume>30</volume>, <fpage>2255</fpage>–<lpage>2265</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2011.138</pub-id></mixed-citation></ref>
<ref id="c82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liepold</surname>, <given-names>T.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2023</year>) <article-title>Matrix Development for the Detection of Phosphorylated Amyloid-β Peptides by MALDI-TOF-MS</article-title>. <source>Journal of the American Society for Mass Spectrometry</source> <volume>34</volume>, <fpage>505</fpage>–<lpage>512</lpage>. <pub-id pub-id-type="doi">10.1021/jasms.2c00270</pub-id></mixed-citation></ref>
<ref id="c83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Soderberg</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2023</year>) <article-title>Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease</article-title>. <source>Neurotherapeutics</source> <volume>20</volume>, <fpage>195</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-022-01308-6</pub-id></mixed-citation></ref>
<ref id="c84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frost</surname>, <given-names>C.V.</given-names></string-name> and <string-name><surname>Zacharias</surname>, <given-names>M</given-names></string-name></person-group>. (<year>2020</year>) <article-title>From monomer to fibril: Abeta-amyloid binding to Aducanumab antibody studied by molecular dynamics simulation. <italic>Proteins: Structure</italic></article-title>, <source>Function, and Bioinformatics</source> <volume>88</volume>, <fpage>1592</fpage>–<lpage>1606</lpage>. <pub-id pub-id-type="doi">10.1002/prot.25978</pub-id></mixed-citation></ref>
<ref id="c85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Watt</surname>, <given-names>A.D.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples</article-title>. <source>Acta Neuropathologica</source> <volume>125</volume>, <fpage>549</fpage>–<lpage>564</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-013-1083-z</pub-id></mixed-citation></ref>
<ref id="c86"><label>86.</label><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Butler</surname>, <given-names>P.M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2025</year>) <article-title>Anti-amyloid antibody equilibrium binding to Abeta aggregates from human Alzheimer disease brain</article-title>. <source>bioRxiv</source> <pub-id pub-id-type="doi">10.1101/2025.05.20.654902</pub-id></mixed-citation></ref>
<ref id="c87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schulte</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>) <article-title>Low-cost synthesis of peptide libraries and their use for binding studies via temperature-related intensity change</article-title>. <source>STAR protocols</source> <volume>2</volume>, <fpage>100605</fpage></mixed-citation></ref>
<ref id="c88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Talucci</surname>, <given-names>I.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>Molecular dissection of an immunodominant epitope in Kv1.2-exclusive autoimmunity</article-title>. <source>Frontiers in Immunology</source> <volume>15</volume>. <pub-id pub-id-type="doi">10.3389/fimmu.2024.1329013</pub-id></mixed-citation></ref>
<ref id="c89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dikmans</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2006</year>) <article-title>SC2: A Novel Process for Manufacturing Multipurpose High-Density Chemical Microarrays</article-title>. <source>QSAR &amp; Combinatorial Science</source> <volume>25</volume>, <fpage>1069</fpage>–<lpage>1080</lpage>. <pub-id pub-id-type="doi">10.1002/qsar.200640130</pub-id></mixed-citation></ref>
<ref id="c90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frank</surname>, <given-names>R</given-names></string-name></person-group>. (<year>1992</year>) <article-title>Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support</article-title>. <source>Tetrahedron</source> <volume>48</volume>, <fpage>9217</fpage>–<lpage>9232</lpage>. <pub-id pub-id-type="doi">10.1016/S0040-4020(01)85612-X</pub-id></mixed-citation></ref>
<ref id="c91"><label>91.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Talucci</surname>, <given-names>I.</given-names></string-name> and <string-name><surname>Maric</surname>, <given-names>H.M</given-names></string-name></person-group>. (<year>2023</year>), <chapter-title>Peptide Microarrays for Studying Autoantibodies in Neurological Disease</chapter-title>, <person-group person-group-type="editor"><string-name><surname>Cretich</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Gori</surname>, <given-names>A.</given-names></string-name></person-group>, <source>Peptide Microarrays</source>), pp. <fpage>17</fpage>–<lpage>25</lpage>, <publisher-name>Springer US</publisher-name></mixed-citation></ref>
<ref id="c92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kreissner</surname>, <given-names>K.O.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>MARTin—an open-source platform for microarray analysis</article-title>. <source>Frontiers in Bioinformatics</source> <volume>4</volume>. <pub-id pub-id-type="doi">10.3389/fbinf.2024.1329062</pub-id></mixed-citation></ref>
<ref id="c93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Case</surname>, <given-names>D.A.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2023</year>) <article-title>AmberTools</article-title>. <source>Journal of Chemical Information and Modeling</source> <volume>63</volume>, <fpage>6183</fpage>–<lpage>6191</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.3c01153</pub-id></mixed-citation></ref>
<ref id="c94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beyer</surname>, <given-names>I.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Solid-Phase Synthesis and Characterization of N-Terminally Elongated Aβ−3–-Peptides</article-title>. <source>Chemistry – A European Journal</source> <volume>22</volume>, <fpage>8685</fpage>–<lpage>8693</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201600892</pub-id></mixed-citation></ref>
<ref id="c95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wiltfang</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> (<year>1991</year>) <article-title>A new multiphasic buffer system for sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins and peptides with molecular masses 100 000–1000, and their detection with picomolar sensitivity</article-title>. <source>Electrophoresis</source> <volume>12</volume>, <fpage>352</fpage>–<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1002/elps.1150120507</pub-id></mixed-citation></ref>
<ref id="c96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haußmann</surname>, <given-names>U.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Analysis of Amino-Terminal Variants of Amyloid-β Peptides by Capillary Isoelectric Focusing Immunoassay</article-title>. <source>Analytical Chemistry</source> <volume>85</volume>, <fpage>8142</fpage>–<lpage>8149</lpage>. <pub-id pub-id-type="doi">10.1021/ac401055y</pub-id></mixed-citation></ref>
<ref id="c97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klafki</surname>, <given-names>H.-W.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2022</year>) <article-title>Detection and quantification of Aβ−3–40 (APP669-711) in cerebrospinal fluid</article-title>. <source>Journal of Neurochemistry</source> <volume>160</volume>, <fpage>578</fpage>–<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.15571</pub-id></mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.106156.2.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lourenco</surname>
<given-names>Mychael V</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1078-0296</contrib-id>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/03490as77</institution-id><institution>Universidade Federal do Rio de Janeiro</institution>
</institution-wrap>
<city>Rio de Janeiro</city>
<country>Brazil</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Convincing</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>Antibodies that selectively bind distinct amyloid-beta variants are vital tools for Alzheimer's disease research. This <bold>valuable</bold> manuscript aims to delineate the epitope specificity in a panel of anti-amyloid-beta antibodies, including some with clinical relevance. The experiments were rigorously conducted, employing an interesting combination of established and state-of-the-art methodologies, yielding <bold>convincing</bold> findings.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.106156.2.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The manuscript by Ivan et al aimed to identify epitopes on the Abeta peptide for a large set of anti-Abeta antibodies, including clinically relevant antibodies. The experimental work was well done and required a major experimental effort including peptide mutational scanning, affinity determinations, molecular dynamics simulations, IP-MS, WB and IHC. The first part of the work is focused on an assay in which peptides (15-18-mers) based on the human Abeta sequence, including some containing known PTMs, are immobilized, thus preventing aggregation and for this reason provide limited biologically-relevant information. Although some results are in agreement with previous experimental structural data (e.g. for 3D6), and some responses to disease-associated mutations were different when compared to wild-type sequences (e.g. in the case of Aducanumab) - which may have implications for personalized treatment. On the other hand, the contribution of conformation (as in oligomers and large aggregates) in antibody recognition patterns was took into consideration in the second part of the study, in which both full-length Abeta in monomeric or aggregated forms and human CSF was employed to investigate the differential epitope interaction between Aducanumab, donanemab and lecanemab. Interestingly, these results confirmed the expected preference of these antibodies for aggregated Abeta. Overall, I understand that the work is of interest to the field.</p>
<p>Comments on revisions:</p>
<p>I have no additional recommendations.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.106156.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Talucci</surname>
<given-names>Ivan</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5617-8869</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Leske</surname>
<given-names>Timon</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Klafki</surname>
<given-names>Hans-Wolfgang</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hassan</surname>
<given-names>Mohammed Mehedi</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Steiert</surname>
<given-names>Annik</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morgado</surname>
<given-names>Barbara</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bothe</surname>
<given-names>Sebastian</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6408-6112</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>van Werven</surname>
<given-names>Lars</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liepold</surname>
<given-names>Thomas</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walter</surname>
<given-names>Jochen</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4678-2912</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Schindelin</surname>
<given-names>Hermann</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2067-3187</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Wiltfang</surname>
<given-names>Jens</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1492-5330</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Wirths</surname>
<given-names>Oliver</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4115-0334</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Jahn</surname>
<given-names>Olaf</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3397-8924</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Maric</surname>
<given-names>Hans Michael</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2719-4752</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Public review):</bold></p>
<p>The manuscript by Ivan et al aimed to identify epitopes on the Abeta peptide for a large set of anti-Abeta antibodies, including clinically relevant antibodies. The experimental work was well done and required a major experimental effort, including peptide mutational scanning, affinity determinations, molecular dynamics simulations, IP-MS, WB, and IHC. Therefore, it is of clear interest to the field. The first part of the work is mainly based on an assay in which peptides (15-18-mers) based on the human Abeta sequence, including some containing known PTMs, are immobilized, thus preventing aggregation. Although some results are in agreement with previous experimental structural data (e.g. for 3D6), and some responses to diseaseassociated mutations were different when compared to wild-type sequences (e.g. in the case of Aducanumab) - which may have implications for personalized treatment - I have concerns about the lack of consideration of the contribution of conformation (as in small oligomers and large aggregates) in antibody recognition patterns. The second part of the study used fulllength Abeta in monomeric or aggregated forms to further investigate the differential epitope interaction between Aducanumab, Donanemab, and Lecanemab (Figures 5-7). Interestingly, these results confirmed the expected preference of these antibodies for aggregated Abeta, thus reinforcing my concerns about the conclusions drawn from the results obtained using shorter and immobilized forms of Abeta. Overall, I understand that the work is of interest to the field and should be published without the need for additional experimental data. However, I recommend a thorough revision of the structure of the manuscript in order to make it more focused on the results with the highest impact (second part).</p>
</disp-quote>
<p>We thank the reviewer for highlighting this critical aspect. Our rationale for beginning with the high-resolution, aggregation-independent peptide microarray was to systematically dissect sequence requirements, including PTMs, truncations, and elongations, at single–amino acid resolution. This platform defines linear epitope preferences without the confounding influence of aggregation and enabled analyses that would not have been technically feasible with fulllength Aβ. This rationale is now clarified in the Introduction (lines 72–77).</p>
<p>At the same time, the physiological relevance of antibody binding can only be assessed in the context of aggregation. Prompted by the reviewer’s comments, we restructured the manuscript to foreground the full-length, aggregation-dependent data (Figures 5–7). These assays demonstrate that Aducanumab preferentially recognizes aggregated peptide over monomers and that pre-adsorption with fibrils, but not monomers, blocks tissue reactivity (lines 585–599; Fig. 5B). They also show that Lecanemab can capture soluble Aβ in CSF by IP-MS (lines 544–547; Fig. 4B, Fig. 6–Supplement 1), and that Donanemab strongly binds low-molecular-weight pyroGlu-Aβ while also recognizing highly aggregated Aβ1-42 (lines 668–684; Fig. 7).</p>
<p>The revised Conclusion now explicitly states the complementarity of the two approaches: microarrays for precise sequence and modification mapping, and full-length aggregation assays for context and physiological relevance (lines 705–714).</p>
<p>Finally, prompted by the reviewer’s feedback, we refined the discussion of therapeutic antibodies to move beyond a descriptive dataset and provide mechanistic clarity. Specifically, the dimerization-supported, valency-dependent binding mode of Aducanumab and the additional structural contributions required for Lecanemab binding to aggregated Aβ are now integrated into the reworked Conclusion (lines 725–741).</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public review):</bold></p>
<p>This paper investigates binding epitopes of different anti-Abeta antibodies. Background information on the clinical outcome of some of the antibodies in the paper, which might be important for readers to know, is lacking. There are no references to clinical outcomes from antibodies that have been in clinical trials. This paper would be much more complete if the status of the antibodies were included. The binding characteristics of aducanumab, donanemab, and Lecanemab should be compared with data from clinical phase 3 studies.</p>
<p>Aducanumab was identified at Neurimmune in Switzerland and licensed to Biogen and Eisai. Aducanumab was retracted from the market due to a very high frequency of the side-effect amyloid-related imaging abnormalities-edema (ARIA-E). Gantenerumab was developed by Roche and had two failed phase 3 studies, mainly due to a high frequency of ARIA-E and low efficacy of Abeta clearance. Lecanemab was identified at Uppsala University, humanized by BioArctic, and licensed to Eisai, who performed the clinical studies. Eisai and Biogen are now marketing Lecanemab as Leqembi on the world market. Donanemab was developed by Ely Lilly and is sold in the US as Kisunla.</p>
</disp-quote>
<p>We thank the reviewer for this valuable suggestion. In the revised manuscript, we have included a concise overview of the clinical status and outcomes of the therapeutic antibodies in the Introduction. This new section (lines 81–99) summarizes the origins, phase 3 trial outcomes, and current regulatory status of Aducanumab, Lecanemab, and Donanemab, as well as mentioning Gantenerumab as a comparator. Key aspects such as ARIA-E incidence, amyloid clearance efficacy, and regulatory decisions are now referenced to provide the necessary clinical context.</p>
<p>These additions directly link our epitope mapping data with the clinical performance and safety profiles of the antibodies, thereby making the translational implications of our results clearer for both research and therapeutic applications.</p>
<disp-quote content-type="editor-comment">
<p>Limitations:</p>
<p>(1) Conclusions are based on Abeta antigens that may not be the primary targets for some conformational antibodies like aducanumab and Lecanemab. There is an absence of binding data for soluble aggregated species.</p>
</disp-quote>
<p>We thank the reviewer for raising this important point. To address the absence of data on soluble aggregated species, we added IP-MS experiments using pooled human CSF as a physiologically relevant source of endogenous Aβ. Lecanemab enriched several endogenous soluble Aβ variants (Aβ1–40, Aβ1–38, Aβ1–37, Aβ1–39, and Aβ1–42), whereas Aducanumab did not yield detectable signals (Figure 4B; lines 544–547). These results directly distinguish between synthetic and patient-derived Aβ and highlight Lecanemab’s capacity to capture soluble Aβ species under biologically relevant conditions.</p>
<disp-quote content-type="editor-comment">
<p>(2) Quality controls and characterization of different Abeta species are missing. The authors need to verify if monomers remain monomeric in the blocking studies for Figures 5 and 6.</p>
</disp-quote>
<p>We thank the reviewer for this comment. In Figure 5 we show that pre-adsorption with monomeric Aβ1–42 does not prevent Aducanumab binding, whereas fibrillar Aβ1–42 completely abolishes staining, consistent with Aducanumab’s avidity-driven preference for higher-order aggregates.</p>
<p>For Lecanemab (Figure 6), we observed a partial preference for aggregated Aβ1–42 over HFIP-treated monomeric and low-n oligomeric forms. We note, as now stated in the revised manuscript (lines 622–623), that monomeric preparations may partially re-aggregate under blocking conditions, which represents an inherent limitation of such experiments.</p>
<p>To further address this, we performed additional blocking experiments using shorter Aβ peptides, which are less prone to aggregation. These peptides did not block immunohistochemical staining (Figure 6 – Supplement 1), underscoring that both epitope length and conformational state contribute to Lecanemab binding. This conclusion is also consistent with recent data presented at AAIC 2023.</p>
<disp-quote content-type="editor-comment">
<p>(3) The authors should discuss the limitations of studying synthetic Abeta species and how aggregation might hide or reveal different epitopes.</p>
</disp-quote>
<p>We thank the reviewer for this important comment. We now explicitly discuss the limitations of using synthetic Aβ peptides, including that aggregation state can mask or expose epitopes in ways that differ from endogenous species. This discussion has been added in the revised manuscript (lines 737–742).</p>
<p>As noted in our replies to Points (2) and (4) here, and to Reviewer #1, we addressed this experimentally by complementing the high-resolution, aggregation-independent mapping with blocking studies using aggregated and monomeric Aβ preparations, and by validating key findings with IP-MS of human CSF as a physiologically relevant source of soluble Aβ. Together, these complementary approaches mitigate the limitations of synthetic peptides and provide a more comprehensive picture of antibody–Aβ interactions</p>
<disp-quote content-type="editor-comment">
<p>(4) The authors should elaborate on the differences between synthetic Abeta and patientderived Abeta. There is a potential for different epitopes to be available.</p>
</disp-quote>
<p>We thank the reviewer for this comment. In the revised manuscript we now discuss how comparisons between synthetic and patient-derived Aβ species reveal additional, likely conformational epitopes that are not accessible in short or monomeric synthetic forms. To address this directly, we performed IP-MS with pooled human CSF. Lecanemab enriched a diverse set of endogenous soluble Aβ1–X species (Aβ1–40, Aβ1–38, Aβ1–37, Aβ1–39, and Aβ1–42), whereas Aducanumab did not yield measurable pull-down (Figure 4B; lines 544– 547). These results emphasize that patient-derived Aβ displays distinct aggregation dynamics and epitope accessibility.</p>
<p>We have expanded on this point in the Conclusion (lines 737–742), underscoring the</p>
<p>importance of integrating both synthetic and native Aβ sources to capture the full range of antibody targets.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Recommendations for the authors):</bold></p>
<p>This revision should prioritize the presentation of results obtained using the full-length Abeta peptide, given its more direct relevance to expected antibody recognition patterns in physiological contexts, and discuss the evidence for using synthetic Abeta.</p>
</disp-quote>
<p>We thank the reviewer for this recommendation. The revised manuscript now places stronger emphasis on results obtained with full-length Aβ peptides, particularly in Figures 5–7, which analyze binding preferences across monomeric, oligomeric, and fibrillar states (lines 585–599, 609–623, 668–684). We also expanded the Discussion to outline both the rationale and the limitations of using synthetic Aβ. The microarray approach provides high-resolution, aggregation-independent sequence and modification mapping, but must be complemented by experiments with full-length Aβ1–42 under physiologically relevant conditions, such as IP-MS from CSF (lines 544–547) and blocking in IHC (lines 585–599, 622–623, 684), to capture conformational epitopes and validate functional relevance.</p>
<disp-quote content-type="editor-comment">
<p>Figure 6. = Please review/better explain the following statement &quot;Lecanemab recognized Aβ140, Aβ1-42, Aβ3-40, Aβ-3-40 and phosphorylated pSer8-Aβ1-40 on CIEF-immunoassay and Bicine-Tris SDS-PAGE/ Western blot, indicating that the Lecanemabbs epitope is located in the N-terminal region of the Aβ sequence&quot;. Is it possible that N-truncated peptides do not form aggregates as efficiently as (or conformationally distinct from) full-length ones?</p>
</disp-quote>
<p>In the revised text we now clarify that Lecanemab recognized Aβ1-40, Aβ1-42, Aβ3-40, Aβ-340, and phosphorylated pSer8-Aβ1-40 on CIEF-immunoassay (Figure 6A; lines 612–619) and Bicine-Tris SDS-PAGE/Western blot (Figure 6C; lines 639–640). In contrast, shorter Ntruncated variants such as Aβ4-40 and Aβ5-40 did not generate detectable signals under the tested conditions. This is consistent with our initial microarray data (Figure 1), which indicated that Lecanemab binding depends on residues 3–7 of the N-terminus.</p>
<p>On gradient Bistris SDS-PAGE/Western blot, Lecanemab showed a partial but not exclusive preference for aggregated Aβ1-42 over monomeric or low-n oligomeric forms in the HFIPtreated preparation (Figure 6B; lines 632–633). Immunohistochemical detection of Aβ deposits in AD brain sections was efficiently blocked by pre-adsorption with monomerized, oligomeric, or fibrillar Aβ1-42 (Figure 6E; lines 643–645), but not by shorter synthetic peptides such as Aβ1-16, Aβ1-34, or Aβ1-38 (Figure 6 – Supplement 1; lines 654–663).</p>
<p>We also note, as now stated in the Results, that re-aggregation of HFIP-treated Aβ1-42 monomers during incubation cannot be entirely excluded (lines 622–623). Taken together, these experiments indicate that both N-terminal sequence length and conformational context are critical for Lecanemab binding, and that truncated peptides may indeed fail to reproduce the aggregate-associated conformations required for full recognition.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations for the authors):</bold></p>
<p>Introduction:</p>
<p>(1) Include examples of Lecanemab, donanemab, and gantenerumab, along with relevant references.</p>
</disp-quote>
<p>We expanded the clinical-context paragraph that already covers Aducanumab, Lecanemab, and Donanemab (lines 81–96) and added Gantenerumab.</p>
<disp-quote content-type="editor-comment">
<p>(2) Address why gantenerumab was not included in the study.</p>
</disp-quote>
<p>Due to the focus of our current study on antibodies with recently approved or late-stage clinical use (Aducanumab, Donanemab, Lecanemab), Gantenerumab was not included.</p>
<disp-quote content-type="editor-comment">
<p>(3) Table 1: Correct the reference for Lecanemab, should be reference 44.</p>
</disp-quote>
<p>Table 1 has been updated to correct the Lecanemab reference.</p>
<disp-quote content-type="editor-comment">
<p>(4) Line 84: Add Uppsala University and Eisai alongside Biogen for Lecanemab.</p>
</disp-quote>
<p>Line 84 has been revised to acknowledge Uppsala University and Eisai alongside Biogen for the development of Lecanemab (lines 90–96).</p>
<disp-quote content-type="editor-comment">
<p>(5) Line 539: Include the reference: &quot;Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. doi: 10.1007/s13311-022-01308-6.</p>
</disp-quote>
<p>We thank the reviewer for drawing attention to this important reference (now cited as Ref. 83) provides a state-of-the-art comparison of binding profiles of Lecanemab, Aducanumab, and Gantenerumab, and we have now properly incorporated it into our manuscript.</p>
<disp-quote content-type="editor-comment">
<p>(6) Line 657-659: State that the findings are also applicable to Lecanemab.</p>
</disp-quote>
<p>Discrepancies between analysis of the short synthetic fragments and the full-length Abeta are now resolved for Aducanumab and Lecanemab and put into context in the results section and the conclusion lines 725-740.</p>
<disp-quote content-type="editor-comment">
<p>(7) Figures 5 and 6: Discuss how to ensure that monomers remain monomers under the study conditions, considering the aggregation-prone nature of Abeta1-42. This aggregation could impact Lecanemab's binding to &quot;monomers.&quot; To our knowledge, Lecanemab does not bind to monomers. The binding properties observed diverge from previously described properties for Lecanemab. Explore reasons for these discrepancies and suggest conducting complementary experiments using a solution-based assay, as per Söderberg et al, 2023. In Figure 6, note that Lecanemab is strongly avidity-driven, potentially causing densely packed monomers to expose Abeta as aggregated, affecting binding interpretation on SDS-PAGE.</p>
</disp-quote>
<p>We thank the reviewer for this important point. In the revised Results and Discussion we explicitly note that HFIP-treated Aβ1–42 monomers may partially re-aggregate during incubation, which cannot be fully excluded (lines 622–623).</p>
<p>To complement these data, we show that Lecanemab successfully enriched soluble endogenous Aβ species (Aβ1–40, Aβ1–38, Aβ1–37, Aβ1–39, and Aβ1–42) in IP-MS from pooled CSF (lines 544–547; Fig. 4B), demonstrating its ability to bind soluble Aβ under physiologically relevant conditions.</p>
<p>We also now cite the Söderberg et al. (2023, PMID: 36253511) study, which reported weak but detectable binding of Lecanemab to monomeric Aβ (their Fig. 1 and Table 6). This supports our interpretation that Lecanemab is aggregation-sensitive rather than strictly aggregationdependent, in contrast to Aducanumab.</p>
<p>To further address sequence and conformational contributions, we performed blocking experiments with shorter, non-HFIP-treated Aβ peptides (Aβ1–16, Aβ1–34, Aβ1–38). These peptides did not block Lecanemab staining in IHC (lines 654–657; Fig. 6 – Supplement 1), indicating that both extended sequence and conformational context are necessary for recognition.</p>
<p>Finally, our findings are in line with preliminary data by Yamauchi et al. (AAIC 2023, DOI: 10.1002/alz.065104), who proposed that Lecanemab recognizes either a conformational epitope spanning the N-terminus and mid-region, or a structural change in the mid-region induced by the N-terminus.</p>
</body>
</sub-article>
</article>